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Summary 31 
Accumulation of mutant proteins is the major cause for many diseases 32 
(proteopathies), and lowering the level of these proteins is highly desired for treatment. 33 
We hypothesized that compounds interacting with both the autophagosome protein 34 
LC31 and the disease-causing protein may target the latter for autophagic clearance. 35 
We tested this hypothesis in the context of lowering mutant HTT protein (mHTT), 36 
which contains an expanded polyglutamine (polyQ) tract and causes Huntington’s 37 
disease (HD), an incurable neurodegenerative disorder2. Through 38 
small-molecule-microarray based screening, we identified four compounds interacting 39 
with both LC3 and mHTT, but not the wild-type HTT protein (wtHTT). Some of these 40 
compounds targeted mHTT to autophagosomes, reduced mHTT levels in an 41 
allele-selective manner, and rescued HD-relevant phenotypes in cells and in vivo in 42 
the fly and mouse HD models. We further revealed that these compounds interacted 43 
with the expanded polyQ stretch and could lower the level of mutant ATXN3, another 44 
disease-causing protein with expanded polyQ3. Our study provides candidate 45 
compounds for lowering mHTT and potentially other disease-causing proteins with 46 
polyQ expansion, demonstrating the concept of lowering disease-causing proteins by 47 
autophagosome-tethering compounds (ATTEC).  48 
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Background 49 
An emerging approach for disease treatment is to lower the levels of 50 
disease-causing proteins, especially those with unknown activities. Biological tools 51 
such as RNAi or CRISPR may achieve this goal4-6, but their clinical delivery is 52 
challenging. Enhancing proteasomal degradation of target proteins by “PROTAC” is a 53 
promising emerging approach7, but proteasomes alone are inefficient in degrading 54 
certain large proteins or aggregates8. Another independent protein degradation 55 
pathway is macroautophagy (referred to as autophagy hereafter), which is a bulk 56 
degradation system that engulfs proteins into autophagosomes for subsequent 57 
lysosomal degradation9. Autophagy is present in all eukaryotic cells, and thus 58 
harnessing the power of autophagy to degrade certain target proteins may open new 59 
windows for drug discovery. Here we investigate this possibility in the context of 60 
lowering mHTT, which contains an expanded polyglutamine (polyQ) stretch (≥36Q) 61 
and causes HD, an incurable monogenetic neurodegenerative disorder2.  62 
mHTT could be degraded by autophagy, during which protein substrates are 63 
engulfed into double-membrane autophagosomes associated with lipidated LC31. We 64 
thus hypothesized that linker compounds interacting with both mHTT and LC3 may 65 
tether them together to enhance the recruitment of mHTT into autophagosomes, 66 
facilitating mHTT degradation. In addition, mHTT-LC3 linker compounds that do not 67 
interact with wtHTT may promote allele-selective degradation of mHTT. Since no 68 
mHTT/LC3-interacting compounds have been reported, we performed 69 
small-molecule-microarray-based screening for desired compounds, and utilized 70 
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wtHTT for the counter-screen to identify allele-selective candidates. 71 
Results 72 
Identification of mHTT-LC3 linker compounds 73 
We stamped 3375 compounds (Fig. 1a) in duplicates into a microarray on 74 
isocyanate-functionalized glass slides via the nucleophile-isocyanate reaction, which 75 
forms covalent bonds between the compounds and the glass slides10,11. We then 76 
purified the human LC3B protein1 (Extended Data Fig. 1a-b & Supplementary Table 1), 77 
a pathogenic mHTT exon1 fragment12 with expanded polyQ (mHTTexon1-Q72), and a 78 
control wtHTT exon1 fragment (HTTexon1-Q25) (Extended Data Fig. 1c-d) for the 79 
screen. We fused a maltose-binding-protein (MBP) tag to both HTT exon1 proteins to 80 
increase their solubility required for later experiments.  81 
To identify LC3B- and mHTT- interacting compounds, we had these purified 82 
proteins flow through the SMMs, and detected the compound-protein interaction using 83 
an optical biosensor, the scanning oblique-incidence reflectivity difference (OI-RD) 84 
microscope. OI-RD is a widely used interaction measurement technology13-15, whose 85 
working principle has been validated and reported previously16-18. We then performed 86 
experiments with HTTexon1-Q25 or buffer alone to exclude non-specific signals, and 87 
identified two compounds that interact with both LC3B and mHTTexon1-Q72, but not 88 
HTTexon1-Q25: 10O5 (GW5074, 89 
3-3-[(3,5-Dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one) and 8F20 90 
(ispinesib, 91 
N-(3-aminopropyl)-N-[(1R)-1-[7-chloro-4-oxo-3-(phenylmethyl)-2-quinazolinyl]-2-meth92 
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ylpropyl]-4-methylbenzamide) (Fig. 1b, annotated based on their ID in the compound 93 
library). We then measured the Kon and Koff of these interactions to confirm our 94 
observation (Fig. 1c-d) and revealed ~100 nM Kd of the compounds’ interaction with 95 
LC3B or mHTTexon1-Q72. As shown in Fig. 1e, these compounds also interacted 96 
with the full-length mHTT (flHTT-Q73, Extended Data Fig. 1e), but not wtHTT 97 
(HTTexon1-Q25 or flHTT-Q23, Fig. 1c&e) or irrelevant proteins (Extended Data Fig. 98 
2a) including MBP-His8 (MBP), superfolder GFP (sfGFP), and Rpn10 (a proteasomal 99 
ubiquitin-receptor) (Extended Data Fig. 1f). We then validated the interaction by an 100 
orthogonal assay, microscale thermophoresis (MST), and obtained consistent results 101 
(Extended Data Fig. 2b).  102 
mHTT-LC3 linker compounds reduced mHTT levels via autophagy in an 103 
allele-selective manner 104 
We then tested if these potential mHTT-LC3 linker compounds decrease mHTT 105 
levels via autophagy as predicted. Both hits decreased levels of mHTT in cultured 106 
primary cortical neurons from a well-established HD knockin mouse model 107 
(HdhQ7/Q140)19 (Fig. 2a), while had little or no effect on levels of wtHTT in the 108 
heterozygous HD neurons (HdhQ7/Q140) (Fig. 2a) and wild-type neurons (HdhQ7/Q7) (Fig. 109 
2b), consistent with their lack of wtHTT interaction. We then looked for other 110 
mHTT-LC3 linker compounds based on the common features of the two hit 111 
compounds 10O5 and 8F20. The –OH group in 10O5 and the –NH2 group in 8F20 112 
were utilized in the nucleophile-isocyanate reaction for stamping of the SMMs, and 113 
these groups were inaccessible to mHTT and LC3B for the compound-protein 114 
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interaction during the screening (Fig. 2c). Thus, while these two hit compounds have 115 
different structures, their exposed chemical groups on the SMMs shared similarities 116 
by containing an aryl ring connected with a lactam-based bicyclic structure with 117 
halogen-substituted aryl group (Fig. 2c). We tested several compounds with similar 118 
features and identified two additional mHTT-LC3 linker compounds (Fig. 2c, AN1 119 
(3-5-Bromo-3-[(3-bromo-4,5-dihydroxyphenyl)methylidene]-1H-indol-2-one) and AN2 120 
(5,7-Dihydroxy-4-phenylcoumarin), for analog1 and analog2, respectively) that 121 
interact with both mHTT and LC3B, but not wtHTT or irrelevant control proteins 122 
(Extended Data Fig. 2c-d). They also reduced the levels of mHTT in an 123 
allele-selective manner in cultured HD mouse neurons (Fig. 2d). No cytotoxicity was 124 
observed in cultured neurons treated with these compounds at the tested 125 
concentration range (Extended Data Fig. 2e), confirming that the mHTT lowering was 126 
not due to cell loss.  127 
Most of these compounds showed an optimal dose (hook effect) in lowering 128 
mHTT (Fig. 2a&d): a sufficient concentration is desired for tethering mHTT and LC3 129 
together, but excessively high concentrations may cause the compound molecules to 130 
interact with mHTT and LC3 separately, without tethering them. Similar concentration 131 
dependent effects were observed in HD patient fibroblasts (Fig. 3c, right panel) and 132 
have been reported for PROTAC20. Consistent with the prediction that the mHTT 133 
lowering is mediated by degradation via autophagy, the autophagy inhibitor NH4Cl or 134 
chloroquine blocked the mHTT-lowering effects (Extended Data Fig. 3a), confirming 135 
that the compounds targeted mHTT for autophagic degradation. Meanwhile, the 136 
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compound-induced mHTT-lowering effects were only slightly enhanced by the mTOR 137 
inhibitor rapamycin, an enhancer of autophagosome formation (Extended Data Fig. 138 
3a, right panels; also see Fig. 3b). 139 
The mHTT lowering could be detected by multiple mHTT antibodies, including 140 
3B5H10, which detects a toxic species of the expanded polyQ stretch21,22 (Fig. 2d, 141 
right panel), suggesting that the detected mHTT lowering was not due to affinity 142 
changes to a specific antibody. In addition, we did not observe any obvious increase 143 
of possible polyQ-containing mHTT fragments at lower molecular weights (Extended 144 
Data Fig. 3b-c), suggesting that the mHTT lowering was not due to increased 145 
site-specific cleavages of mHTT. 146 
We further investigated the compounds’ effects in HD patient cells by the 147 
well-established HTRF (Homologous Time-Resolved Fluorescence) assay23,24, which 148 
is more quantitative than Western-blots, although inapplicable to mouse mHTT 149 
proteins due to non-specific signals25. We observed autophagy-dependent lowering of 150 
mHTT by these compounds in HD patient fibroblasts and iPSC-derived neurons (Fig. 151 
3a-b&Extended Data Fig. 3d), but not wtHTT in the wild-type or Parkinson’s disease 152 
(PD) patient fibroblasts (Fig. 3a). To further confirm the role of autophagic degradation, 153 
we tested the compounds’ effect with or without lowering of ATG5, a key autophagy 154 
gene required for autophagosome formation26. ATG5 knockdown in HD patient 155 
fibroblasts (Q47) significantly decreased LC3-II and nullified the mHTT lowering 156 
effects induced by the mHTT-LC3 linker compounds (Extended Data Fig. 3e). Similar 157 
results were obtained in ATG5 knockout mouse embryonic fibroblasts26 (MEFs, 158 
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Extended Data Fig. 3f), confirming that the compounds’ effects were mediated by 159 
autophagic degradation. 160 
The two hit compounds 10O5 and 8F20 are known to inhibit c-Raf and KSP27,28, 161 
respectively, whereas AN1 and AN2 had unknown activities on these targets. We thus 162 
tested their potential influences on c-Raf and KSP. Based on the in vitro c-Raf kinase 163 
assay, 10O5, the known c-Raf inhibitor, but not the other three compounds inhibited 164 
c-Raf at the concentrations tested (Extended Data Fig. 4a). We then tested Mek/Erk 165 
phosphorylation levels in the cultured neurons treated with these compounds at 166 
optimal mHTT-lowering concentrations to evaluate Raf activity29 and found no 167 
significant effects of all tested compounds (Extended Data Fig. 4b, left panel). We 168 
also tested phospho-BUBR1 levels to evaluate KSP activities30, and observed no 169 
significant effects either (Extended Data Fig. 4b, right panel). We made similar 170 
observations in the HD patient fibroblasts (Q47) (Extended Data Fig. 4c). Thus, the 171 
observed mHTT-lowering is probably irrelevant to c-Raf or KSP inhibition. To further 172 
confirm this, we examined the effects of several known c-Raf or KSP inhibitors, and 173 
found that they had no HTT-lowering effects (Fig. 3c, left panel). Two of these 174 
inhibitors, PLX-4720 and BAY1217389, have structures somewhat similar to 10O5 175 
and 8F20, respectively (Fig. 3c, middle panel). They showed no effects in lowering 176 
mHTT in patient cells at sub-micromolar concentrations (Fig. 3c, right panel), probably 177 
because they had very weak affinity to LC3 and mHTT, if any (Extended Data Fig. 2c, 178 
right panels). In comparison, AN2 showed a dose-dependent mHTT lowering in the 179 
same cells (Fig. 3c, right panel). 180 
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We then investigated the compounds’ effects in vivo. Since the Drosophila LC3 181 
homolog Atg8 has a predicted structure highly similar to LC3B (Extended Data Fig. 182 
5a), we tested the compounds in HD transgenic flies expressing human full-length 183 
mHTT. All of the discovered mHTT-LC3 linker compounds significantly reduced mHTT 184 
levels (Extended Data Fig. 5b), validating the in vivo efficacy of these compounds.  185 
We further investigated the compounds’ effects in vivo in the HD knockin mouse 186 
model (HdhQ7/Q140)19 by intracerebroventricular (icv) injections. Three out of the four 187 
linker compounds (10O5, AN1 or AN2, but not 8F20) led to significant lowering of 188 
mHTT in cortices of HD mice (Extended Data Fig. 6a). We then performed 189 
intraperitoneal (ip) injection of 10O5 and AN2 at 0.5 mg/kg in HD knockin mice. The 190 
compounds crossed the blood-brain barrier and reached the brain at detectable 191 
concentrations (Extended Data Fig. 5c, ~20 to 200 nM for 10O5 and ~20 to 40 nM for 192 
AN2; no signal was detected in the DMSO injected control group) 0.5 ~ 6 hours after 193 
injection. Consistent with this, we observed significant allele-selective lowering of 194 
mHTT in mouse cortices and striata (Extended Data Fig. 6b-c). The observed 195 
lowering was not due to changes in mHTT solubility, because no increase of mHTT 196 
aggregates was observed in the cortical tissues of mice treated with these 197 
compounds (Extended Data Fig. 6d).  198 
mHTT-LC3 linker compounds tethered mHTT to autophagosomes 199 
We then examined whether these compounds truly function as linkers between 200 
mHTT and LC3 to target mHTT for autophagosome engulfment. Presence of 10O5 or 201 
AN2, the two compounds that were effective in vivo by ip-injection, markedly 202 
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enhanced the mHTT-LC3 interaction in the in vitro pull-down experiments (Fig. 4a, 203 
comparing lane 11 with 12&13; Fig. 4b, comparing lane 11 with 12 for both upper and 204 
lower panels). No enhancement effect was observed for the wtHTT-LC3 interaction 205 
(Fig. 4a, lane 8-10; Fig. 4b, lane 9-10 in both upper and lower panels). Consistent with 206 
this, these compounds led to elevated engulfment of mHTT by autophagosomes both 207 
in transiently transfected HeLa cells expressing exogenous GFP-LC3B and 208 
HTTexon1-MBP-His fragments (Fig. 4c), and in mouse striatal cells (STHdhQ111/Q111)31 209 
expressing endogenous LC3 and full-length mHTT proteins (Fig. 4d).  210 
The data above confirmed that the compounds tethered mHTT and 211 
LC3B/autophagosomes in vitro and in cells, although the detailed structural 212 
information remains to be resolved.  213 
mHTT-LC3 linker compounds did not influence autophagy function and reduced 214 
mHTT in a relatively specific manner 215 
The mHTT-lowering by the linker compounds was unlikely due to an 216 
enhancement of autophagy functions, because the number and size of 217 
autophagosomes remained unchanged (Extended Data Fig. 7a). We then further 218 
investigated whether the compounds could influence autophagy by established 219 
approaches in the literature32-34. Neither 10O5 nor AN2 influenced the 220 
autophagosome-lysosome fusion or autophagy activity (Extended Data Fig. 7b-d). 221 
Furthermore, we observed no changes of the LC3-II level in the cultured cortical 222 
neurons treated with 10O5 or AN2 in the absence or presence of the lysosome 223 
inhibitor bafilomycin-A1 (bafA1) (Extended Data Fig. 7e). The level of the known 224 
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autophagy-selective substrate protein SQSTM1/p62 was also unaffected in vivo and 225 
in cultured neurons (Extended Data Fig. 7f & 8a). In addition, other wild-type polyQ 226 
proteins (Atxn3 and Tbp) and control proteins (Nbr1, Ncoa4, Actin, Gapdh, Tubulin) 227 
were not influenced (Extended Data Fig. 8a, all changes < 10%).  228 
We then performed proteomics analysis to obtain a more complete scope of 229 
proteins that may have been influenced. We observed significant lowering (~20%, p < 230 
0.01) of HTT levels in cortices of mice ip-injected with 10O5 or AN2 (Extended Data 231 
Fig. 8b, bar plots). Considering that the proteomics analysis was unable to distinguish 232 
mHTT from wtHTT, the actual mHTT lowering was expected to be more. Meanwhile, 233 
using the criteria of p < 0.01, we observed changes of only a small percentage of 234 
proteins (Extended Data Fig. 8b, and see Supplementary Table 2 for details). No 235 
autophagy-specific substrate proteins exhibited significant changes and there was no 236 
enrichment of autophagy pathway-related proteins (Supplementary Table 2), further 237 
confirming that autophagy was unaffected. Proteomics analysis in cultured neurons 238 
revealed consistent results (Extended Data Fig. 8c, and see Supplementary Table 3 239 
for details).  240 
mHTT-LC3 linker compounds lowered other proteins with expanded polyQ 241 
The discovered linker compounds interacted with and lowered mHTT but not 242 
wtHTT (Fig. 1). The simplest explanation is that the compounds specifically interact 243 
with the expanded polyQ tract, possibly by recognizing its emergent conformation that 244 
is different from the short polyQ stretch21,35. If so, the discovered linker compounds 245 
may reduce other proteins with expanded polyQ. Consistent with this prediction, the 246 
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linker compounds 10O5, AN1 and AN2 reduced the levels of mutant but not wild-type 247 
ATXN3 in SCA3 patient fibroblasts (Extended Data Fig. 9a) and exogenously 248 
expressed 72Q-GFP, 46Q-GFP, 38Q-GFP but not 25Q-GFP proteins (containing just 249 
the Met-polyQ-sfGFP sequences) in HEK293T cells (Extended Data Fig. 9b). These 250 
data suggest that the compounds distinguished the expanded from the short polyQ 251 
stretch at a threshold between 25Q and 38Q. To further confirm this, we tested the 252 
compound-polyQ interactions (Extended Data Fig. 9c), and confirmed that 10O5, AN1 253 
and AN2 interacted with polyQ-GFP with 38Q or longer polyQ, but not 25Q-GFP or 254 
GFP alone (Extended Data Fig. 9d-e; Extended Data Fig. 2).  255 
mHTT-LC3 linker compounds rescued HD-relevant phenotypes 256 
We further investigated the therapeutic potential of the compounds in treating HD. 257 
All the mHTT-LC3 linker compounds rescued mHTT toxicity in HD patient 258 
iPSC-derived neurons (Fig. 5a-b). They also rescued HD-relevant behavioral deficits 259 
and increased the lifespan of flies expressing human mHTT, while having no influence 260 
on the flies expressing wtHTT (Fig. 5c). 261 
Finally, we investigated the disease-relevant behavioral phenotypes in 10-months 262 
old heterozygous HD knockin mouse (HdhQ7/Q140). Significant deficits of HD mice were 263 
observed in several behavioral tests including rotarod, balance beam, and gripping 264 
force tests, while the DMSO (110 μg/kg) injection alone did not have an effect 265 
(Extended Data Fig. 9f-h). In comparison, ip injection of the 10O5 or AN2 significantly 266 
improved HD-relevant behavioral deficits in these tests, without influencing the 267 
wild-type mice (Fig. 5d-f), demonstrating a rescue of HD-relevant phenotypes. This is 268 
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a proof of principle study, and further investigations will be required to establish the 269 
suitability for therapeutic application. 270 
Discussion 271 
In this study, we have identified mHTT-LC3 linker compounds that were able to 272 
reduce mHTT levels at ~nM concentrations in HD cells and at 0.5 mg/kg by ip 273 
injection in vivo (Extended Data Table 1). The compounds did not influence wtHTT, 274 
which has essential functions especially during development and young adulthood36. 275 
These features of the compounds are highly desired for HD treatment or potentially 276 
other polyQ diseases (Extended Data Fig. 9a-e), although preclinical studies of 277 
longitudinal efficacy and safety are necessary for therapeutic development.  278 
From a broader perspective, we demonstrate the concept of using small molecule 279 
compounds to “glue” the target protein (mHTT) and LC3 for autophagic degradation 280 
(Fig. 5g). We selected mHTT as our target protein, because wtHTT provides a perfect 281 
control for screening. We had the fortune to discover hits that interact with both LC3B 282 
and mHTT. If no such hits had been identified, linker compounds could still be 283 
generated by conjugating an mHTT-interacting compound and an LC3-interacting 284 
compound by the nucleophile-isocyanate reaction utilized for the stamping of SMMs. 285 
To develop this concept, the critical next step is to resolve the core chemical 286 
compartment that interacts with LC3 without influencing its function. Comprehensive 287 
medicinal chemistry and structural studies are needed to resolve the compound-LC3 288 
interaction interface, which may then be developed to a general degradation tool for 289 
conjugation with other compounds interacting with specific targets of interest.  290 
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 In summary, we have identified mHTT-LC3 linker compounds that are capable of 291 
lowering mHTT in vivo in an allele-selective manner, and demonstrated the possibility 292 
of utilizing autophagosome-tethering compounds (ATTEC) to lower target proteins, 293 
providing new entry points for drug discovery. 294 
 295 
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Main figure legends 406 
Figure 1. Identification of potential mHTT-LC3 linker compounds by SMM-based 407 
screening and validation 408 
a) The OI-RD image of a small molecule microarray (SMM). Each compound was 409 
printed in duplicates in adjacent vertical positions.  410 
b) Magnified view of surface mass density changes after incubation with 411 
HTTexon1-Q25-MBP, HTTexon1-Q72-MBP, and LC3B, respectively. Two hits (10O5 412 
and 8F20) were highlighted by red rectangular boxes.  413 
c-e) Association-dissociation curves of surface immobilized compounds 8F20 and 414 
10O5 with HTTexon1-Q72-MBP (Q72), HTTexon1-Q25-MBP (Q25), LC3B, full-length 415 
HTT-Q73 (Q73), or full-length HTT-Q23 (Q23) at the indicated concentrations of 416 
purified proteins. For details see “Methods”. 417 
 418 
Figure 2. mHTT-LC3 linker compounds lowered mHTT but not wtHTT through 419 
autophagy in cultured mouse neurons. 420 
a) Western-blots (HTT detected by the 2166 antibody) and quantifications of 421 
compound-treated cultured cortical neurons from HdhQ7/Q140 HD knockin mice. The 422 
statistical analysis was performed by two-way ANOVA tests. For 10O5, F (1, 72) = 423 
50.93, p<0.0001; for 8F20, F (1, 40) = 8.903, p=0.0048. 424 
b) Representative Western-blots (from 3 biological repeats) of cultured wild-type 425 
cortical neurons treated with the indicated compounds.  426 
c) 2D-structures of the hit compounds and the other effective linker compounds 427 
identified. The red lines indicate the glass-chips used to stamp the hit compounds. 428 
The dotted ovals indicate the possible chemical groups exposed for 429 
protein-compound interactions in the screening.  430 
d) Left and middle panels: similar to a), but treated with the compounds AN1 or AN2. 431 
For AN1, F (1, 70) = 32.96, p<0.0001; For AN2, F (1, 69) = 23.03, p<0.0001. Right 432 
panels: similar to a), but blotted with different HTT antibodies (10O5 and 8F20: 100nM; 433 
AN2: 50 nM). 434 
For all panels, n indicates the number of independently plated wells, and bars 435 
represent mean and s.e.m.. Full-blots of cropped gels are shown in Extended Data 436 
Fig. 3b or Supplementary Fig. 1. 437 
 438 
Figure 3. mHTT-LC3 linker compounds lowered mHTT in HD patient cells. 439 
a) HTT levels measured by HTRF (2B7/MW1 for mHTT, and 2B7/2166 for total HTT) 440 
in the indicated HD, WT or PD patient primary fibroblasts treated with the indicated 441 
compounds (100 nM). All signals were normalized to the averaged signals from the 442 
DMSO control group. The statistical analysis was performed by one-way ANOVA with 443 
post-hoc Dunnett’s tests. “****”: p<0.0001.  444 
b) Similar to a), but in immortalized HD patient fibroblasts treated with or without the 445 
autophagy inhibitors NH4Cl/chloroquine/bafilomycin-A1, or the autophagy enhancer 446 
rapamycin. 447 
c) Left panel: similar to a), but in immortalized HD patient fibroblasts (Q47) treated 448 
with indicated c-Raf or KSP inhibitors at 100 nM. Middle panel: 2D structure of 449 
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inhibitors. The dotted ovals indicate the parts of the compounds that share similarities 450 
with the hit compounds. Right panel: dose-dependent curves of the indicated 451 
compounds. 452 
For all panels, n indicates the number of independently plated wells, and bars 453 
represent mean and s.e.m.. 454 
 455 
Figure 4. Linker compounds enhanced mHTT-LC3 interaction and tethered 456 
mHTT to autophagosomes 457 
a-b) Representative results (from 3 biological repeats) of in vitro pull-down 458 
experiments using purified HTT and LC3B proteins. For details see “Methods”. 459 
c-d) Representative images (scale bar: 10 μm) and quantifications of the 460 
co-localization between HTT and autophagosomes. For details see “Methods”. 461 
Bars present mean and s.e.m.. The n number indicates the number of cells. The 462 
statistical analysis was performed by one-way ANOVA with post-hoc Dunnett’s tests. 463 
“****”: p<0.0001.  464 
 465 
Figure 5. Linker compounds rescued HD-relevant phenotypes in cells and in 466 
vivo. 467 
a) Representative immunostaining images (scale bar: 50 μm) and quantifications of 468 
the neuronal specific tubulin marker TUBB3 and DAPI staining showing neuronal 469 
morphology of patient iPSC-derived striatal neurons (HD: Q47; WT: Q19) treated with 470 
indicated compounds. For details see “Methods”.  471 
b) Neuronal apoptosis measurement at different time points after BDNF removal using 472 
a green fluorescent dye (NucView 488) detecting active caspase-3. For details see 473 
“Methods”. 474 
c) Left: Kaplan-Meier survival curves of transgenic Drosophila with the indicated 475 
transgenes and compound treatments. Right: similar to the left panel, but plotting the 476 
climbing performance as a function of age after eclosion. For details see “Methods”.  477 
d-f) Mouse behavioral tests showing the improvement of HD-relevant phenotypes by 478 
ip-injection of the indicated compounds at 0.5 mg/kg. For details see “Methods”. 479 
g) A schematic model showing how mHTT-LC3 linker compounds may induce mHTT 480 
degradation, illustrating the concept of lowering target proteins by 481 
autophagosome-tethering compounds (ATTEC). The images representing HTT 482 
proteins were published previously37. 483 
 484 
  485 
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Methods 486 
Additional details of figure legends 487 
Figure 1. Identification of potential mHTT-LC3 linker compounds by SMM-based 488 
screening and validation. 489 
c-e) For all association-dissociation curves, vertical dash lines mark the starts of 490 
association and dissociation phases of the binding event. The red dash curves are 491 
global fits to a Langmuir reaction model with the fitting parameters listed at the bottom 492 
of each plot. No binding signals were observed for HTTexon1-Q25-MBP or full-length 493 
HTT-Q23 proteins, and thus the parameters were not presented. 494 
Figure 4. Linker compounds enhanced mHTT-LC3 interaction and tethered mHTT 495 
to autophagosomes. 496 
a-b) For MBP pull-down (a), purified HTTexon1-MBP (10 μg) or MBP (10 μg) bound 497 
MBP-resin were incubated with the purified LC3B protein (40 μg) and the indicated 498 
compounds. The HTTexon1-MBP or the MBP proteins were pulled down and the 499 
eluates were tested for co-precipitated LC3B. 4% of the total eluate was loaded in 500 
each lane, and the input : pull-down loading ratio was 100%. Both 10O5 and AN2 501 
enhanced LC3B’s interaction with HTTexon1-Q72-MBP, but not HTTexon1-Q25-MBP. 502 
Note that the MBP blot signals were much weaker for the Q72 protein, possibly 503 
because recognition of the MBP tag by the antibody was affected in the fusion protein. 504 
Meanwhile, data interpretation was not influenced, because compound treatments did 505 
not alter the MBP signals for the Q72 protein (last three lanes). The GST pull-down (b) 506 
was performed similarly, except using full-length HTT-Q73 or full-length HTT-Q23 507 
(both without fusion tags) and GST-LC3B proteins for the in vitro GST pull-down 508 
experiments to precipitate GST-LC3B or GST alone with its binding proteins, and then 509 
eluted for detection. Note that the pull-down is in the reverse direction of the pull-down 510 
in (a). The input : pull-down loading ratio for the GST blot was 100%, whereas the 511 
ratio for the HTT blot was 10% to avoid over-exposure of the input. Both 10O5 and 512 
AN2 enhanced LC3B’s interaction with the full-length HTT-Q73 but not the full-length 513 
HTT-Q23 protein.  514 
c-d) Representative confocal microscopy images (scale bar: 10 μm) and 515 
quantifications of the co-localization between HTTexon1-MBP-His (red, detected by 516 
anti-His immunofluorescence) and LC3B-GFP (green, detected by GFP fluorescence 517 
directly) in transiently transfected HeLa cells (c) or between endogenous mHTT and 518 
LC3-II in the HD knockin mouse striatal cells (STHdhQ111/Q111) (d). For over-expressed 519 
proteins (c), the LC3B-GFP alone transfected or the HTTexon1-MBP-His alone 520 
transfected cells were imaged at both channels to ensure the specificity of the signals 521 
(upper panels). The white arrows indicate representative co-localization puncta. Parts 522 
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of the images have been amplified to show co-localization puncta more clearly 523 
(pointed by orange arrows). Since the puncta were obvious, co-localization was 524 
analyzed by counting the red+green+ (yellow) and the total red+ puncta directly, and 525 
then calculate their ratio for each cell. Blind analysis was performed for quantifications. 526 
For endogenous proteins (d), mHTT was detected by the anti-HTT antibody 2166, and 527 
the endogenous LC3-II was detected by an anti-LC3 antibody that has been reported 528 
to specifically detect LC3-II32. Since the signals of endogenous proteins were more 529 
dispersed, the co-localization analysis was performed blindly by measuring the 530 
red+green+ (yellow) and the total red+ pixels by ImageJ, and then calculate their ratio 531 
for each cell.   532 
 Figure 5. Linker compounds rescued HD-relevant phenotypes in cells and in vivo. 533 
a) Loss of processes and shrinkage of neurons were observed in HD neurons after 534 
BDNF removal. Bar plots: quantification of the TUBB3 signal covered area (TUBB3 535 
area) normalized to the nuclei counts based on DAPI. The lower TUBB3 area per cell 536 
reflects neuronal processes shrinkage and loss. Data were normalized to the average 537 
of WT controls. The statistical analysis was performed by one-way ANOVA (F (5, 60) = 538 
94.78) with post-hoc Dunnett’s tests: “****”: p<0.0001. The n number indicates the 539 
number of independently plated wells. 540 
b) The images were captured every 3 hours inside the incubator using Incucyte, and 541 
the caspase-3 active cells were quantified by the fluorescent object count per field. 542 
The statistical analysis was performed by two-way ANOVA (F (43, 516) = 12.85) with 543 
post-hoc Dunnett’s tests, comparing to the HD_DMSO group. “****”: p<0.0001. The 544 
numbers in brackets indicate the number of independently plated wells, with 4 fields 545 
per well imaged and averaged for quantification. Three batches were tested and 546 
showed consistent results. 547 
c) Left: the Drosophila expressed full-length HTT proteins (Q128 or Q16) in the 548 
nervous system driven by elav-GAL4. 75 flies were tested for each group. The 549 
statistics was performed by Log-rank (Mantel-Cox) test, comparing compound treated 550 
groups with DMSO controls in Q128 flies. ****: p < 0.0001. Right: similar as the left 551 
panel, but plotting the climbing performance as a function of age after eclosion. The 552 
statistics was performed by two-way ANOVA (F (4, 275) = 122.1) with post-hoc 553 
Dunnett’s tests, comparing the compound treated groups with the DMSO controls in 554 
Q128 flies. Numbers in brackets indicate the number of vails (each containing 15 flies) 555 
tested. ****: p < 0.0001. 556 
d-f) The numbers in brackets indicated the number of mice tested. The statistical 557 
analysis was performed by two-way ANOVA with post-hoc Dunnett’s tests, and the p 558 
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values compared with the DMSO control were indicated (“****”: p<0.0001). For HD 559 
mice, F (2, 195) = 4.963 in rotarod tests, F (2, 195) = 37.31 in balance beams tests, 560 
and F (2, 156) = 7.068 in gripping force tests. No significant difference was detected in 561 
the wild-type mice injected with different compounds. The investigators were blinded 562 
to the compounds and genotypes when performing the experiments. In all panels, the 563 
error bars represent mean and s.e.m.. 564 
Compound stamping on the microarray 565 
Small molecule microarrays (SMMs) containing 3,375 bioactive compounds were 566 
used for high-throughput screening of target proteins. The compound library 567 
containing 1,527 drugs approved by Food and Drug Administration (FDA) of United 568 
States, 1,053 natural products from traditional Chinese medicine, and 795 known 569 
inhibitors were stamped onto the SMMs. Each compound was dissolved in DMSO at 570 
a concentration of 10 mM and printed in duplicates along vertical direction on 571 
homemade phenyl-isocyanate functionalized glass slides with a contact microarray 572 
printer (SmartArrayer 136, CapitalBio Corporation). Biotin-BSA at a concentration of 573 
7,600 nM in 1× phosphate-buffered saline (PBS) and biotin-(PEG)2-NH2 at a 574 
concentration of 5 mM in DMSO were printed as the inner and outer borders of SMMs, 575 
respectively. The diameter of each spot was about 150 μm and spacing between two 576 
adjacent spots was 250 μm. The printed SMMs were then dried at 45 °C for 24 h to 577 
facilitate covalent bonding of nucleophilic groups of small molecules to isocyanate 578 
groups of the functionalized slides. Afterwards, the SMMs were stored in a -20 °C 579 
freezer. 580 
Expression and purification of recombinant proteins 581 
The human microtubule associated protein 1 light chain 3 beta (MAP1LC3B, 582 
LC3B) gene (GenBank: NM_022818.4) was amplified by PCR and cloned into a 583 
pGEX-6P1 (GE Healthcare) derived vector pGHT, which is a prokaryotic expression 584 
vector reconstructed by adding a His8 tag and a TEV protease cleavage site before 585 
the pGEX-6P1 multiple cloning site. After sequencing verification, the expression 586 
plasmid pGHT-LC3B was introduced into Escherichia coli BL21 (DE3) pLsyS, in which 587 
the recombinant GST-LC3B protein was expressed by IPTG induction. When the 588 
bacterial culture reached OD600=0.8, its temperature was decreased to 18 °C, and 0.2 589 
mM IPTG was added into the culture for an additional 20 h incubation. The cells were 590 
then harvested by centrifugation (6,000g, 4 °C, 15 min) and the cell pellet was 591 
suspended in 50 mM Tris-HCl buffer, pH 7.5, with 150 mM NaCl and 5% glycerol. 592 
Cells were then disrupted by sonication, followed by centrifugation (20,000g, 4 °C, 60 593 
min). The supernatants were then loaded onto a HisTrap HP column (GE Healthcare, 594 
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cat. no. 17524701), and eluted with 50 mM Tris-HCl buffer, pH 7.5, containing 150 mM 595 
NaCl, 5% glycerol and 300 mM imidazole. The LC3B eluate was then mixed with TEV 596 
protease (Sigma, cat. no. T4455; eluted protein: TEV protease = 100:1) and dialyzed 597 
against the dialysate buffer (50 mM Tris-HCl buffer, pH 7.5, containing 100 mM NaCl) 598 
in 4 °C overnight. After TEV protease treatment, the samples were then loaded onto a 599 
HisTrap HP column again, the flow through fraction which mainly contains tag 600 
removed recombinant LC3B. Afterwards, the proteins were concentrated and further 601 
purified by Superose 6 Increase 10/300 GL (GE Healthcare) size exclusive 602 
chromatography. Finally, the purified proteins were concentrated to approximately 10 603 
mg/ml in 50 mM HEPES buffer with 100 mM NaCl for further analysis. The MBP-His8 604 
and Rpn10 proteins were purified similarly. 605 
The full-length HTT proteins, HTTexon1-MBP, polyQ-sfGFP and sfGFP proteins 606 
were purified from mammalian cells. For full-length HTT proteins, the human HTT 607 
gene (GenBank: NM_002111.8) with (CAG)23 or (CAG)73 (23Q or 73Q for proteins) 608 
were de novo synthesized (by Genewiz Inc.), sequence validated and then cloned into 609 
a modified pCAG vector with an N-terminal protein A tag. The plasmid was transfected 610 
to human embryonic kidney E293 cells using polyethylenimine (PEI, from 611 
Polysciences, cat. no. 23966). After culture at 37 °C for 48 to 60 h, cells were 612 
collected and lysed at 4 °C for 1 h in lysis buffer containing 50 mM Tris-HCl, pH 8.0, 613 
150 mM NaCl, 5% glycerol, 0.5% CHAPS, 3 mM DTT, 1% PMSF, 1 μg/ml pepstatin, 1 614 
μg/ml leupeptin and 1 μg/ml aprotinin, 5 mM ATP and 5 mM MgCl2. After 615 
centrifugation at 15000 rpm for 40 min, the supernatants were then incubated with 616 
IgG monoclonal antibody-agarose (Smart-lifesciences, cat. no. SA030010) for 2 h and 617 
unbound proteins were extensively washed away. The HTT proteins were then 618 
digested using TEV protease overnight to remove the protein A tag and eluted protein 619 
was further purified by ion exchange and gel filtration chromatography using Mono Q 620 
and Superose 6 (5/150 GL) columns from GE healthcare. The peak fractions were 621 
pooled for further biochemical analysis. The HTTexon1 with 25Q or 72Q cDNA were 622 
also de novo synthesized and cloned into a mammalian expression vector 623 
pTT5SH8Q2 for large scale production in HEK293T cells. In order to improve the 624 
production yield and increase the solubility, a C terminal MBP tag was added after the 625 
HTTexon1 sequences to generate the pTT-HTTexon125Q-MBP and 626 
pTT-HTTexon125Q-MBP plasmids. For protein production and purification, the 627 
HEK293T cells were transfected by pTT-HTT25QExon1-MBP and 628 
pTT-HTT72QExon1-MBP plasmids with linear PEI (PolySciences #24765), and then 629 
collected after 48 h. The cells were then lysed by sonication in buffer containing 50 630 
mM Tris-HCl, pH 7.5, 150 mM NaCl, 20 mM imidazole, 5% glycerol, protease inhibitor 631 
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cocktail (Sigma) and 50U/ml benzonase (Sigma). After centrifugation, the 632 
supernatants were loaded onto HisTrap HP column (GE Healthcare), and eluted with 633 
the buffer containing 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 300 mM imidazole, 5% 634 
glycerol and protease inhibitor cocktail. The MBP tag was not cleaved to avoid 635 
precipitation. Afterwards, the proteins were concentrated and further purified by 636 
Superose 6 Increase 10/300 GL (GE Healthcare) size exclusive chromatography.  637 
Verifications of the recombinant proteins by matrix assisted laser desorption 638 
ionization-time of flight mass spectrometry (MALDI-TOF). 639 
The purified LC3B, HTTexon1Q25-MBP, and HTTexon1Q72-MBP proteins were 640 
dialyzed into 5 mM NH4Ac by Superose 6 Increase size exclusive chromatography for 641 
linear mode MALDI-TOF analysis on a Bruker FLEX MALDI-TOF instrument. A total of 642 
1500-2500 scans were averaged for each spectrum using an accelerating voltage of 643 
25 kV. Sinapinic acid (SA, Bruker, cat. no. 820135) was used as the matrices for 644 
protein and peptide analyses. SA was made into 20 mg/mL solutions in 70% ACN, 0.1% 645 
TFA. For the acquisition of spectra from 10,000 to 100,000 amu, 2 µL of sample was 646 
mixed with 2 µL of SA solution in an Eppendorf tube, and 2 µL of the mixture was 647 
loaded onto the MALDI plate. The calibration peptides for this range were BSA (M + 648 
66431) (Sigma, cat. no. A1933). All spectra were obtained in positive linear mode. 649 
The amount of full-length HTT proteins were limited, and thus not validated by 650 
MALDI-TOF. Instead, they were further purified by ion exchange and gel filtration 651 
chromatography, and validated by Coomassie-blue staining (Extended data Fig. 1e) 652 
and Western-blots (Fig. 4b). 653 
Verifications of the recombinant LC3B by X ray diffraction crystallography 654 
Since the deletion of G120 (lipidation site) stabilizes LC3B protein, we utilized 655 
LC3BΔG120 protein to get high resolution diffraction data. Purified LC3BΔG120 656 
protein was concentrated in the following buffer: 20 mM HEPES pH7.5, 150 mM NaCl. 657 
The LC3BΔG120 crystal was grown in reservoir solutions consisting of 0.16 M 658 
ammonium sulfate, 0.08 M sodium acetate pH 4.6, 20% (w/v) PEG4000, 20% (v/v) 659 
glycerol and 0.01 M Taurine.  660 
Refinement 661 
The X-ray diffraction data were collected at 100 K in the beamline BL17U1 and 662 
BL19U1, SSRF. The wavelength for data collection was 0.97892 Å. Diffraction images 663 
were indexed and processed by HKL2000. The structure of LC3B∆G120 (PDB ID 664 
6J04, 1.90Å) was solved by molecular replacement with the Phaser 2.8 program from 665 
the CCP4 crystallography package using the (PDB ID code 1UGM) as the search 666 
model. The refinement was performed by Refmac 5.5 and Phenix 1.14. There are no 667 
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Ramachandran outliers to report. The related figure was drawn using PyMOL 2.2.  668 
Compound-protein interaction measurements by oblique-incidence reflectivity 669 
difference (OI-RD)  670 
For high-throughput preliminary screening of target proteins, a SMM was 671 
assembled into a fluidic cartridge and washed in situ with a flow of 1× PBS to remove 672 
excess unbound small molecules. After washing, the SMM was scanned with a 673 
label-free OI-RD scanning microscope to image small molecules immobilized on glass 674 
slides. After it was blocked with 7,600 nM BSA in 1× PBS for 30 min, SMM was 675 
incubated with the target protein for 2 h. HTTexon1-Q25-MBP at a concentration of 676 
454 nM, HTTexon1-Q72-MBP at a concentration of 238 nM, and LC3B at a 677 
concentration of 680 nM were screened on separate fresh SMMs. OI-RD images were 678 
scanned for each operation, including washing, blocking, and incubation. The OI-RD 679 
difference images (images after incubation – images before incubation) were utilized 680 
for analysis, and vertical bright doublet spots indicated compounds that bind with 681 
target proteins in both replicates. 8F20 and 10O5 were identified to bind to 682 
HTTexon1-Q72-MBP and LC3B, but not HTTexon1-Q25-MBP. The binding was 683 
further confirmed by the kinetics measurements (see below). 684 
To measure binding kinetics of target proteins with compounds, we prepared new 685 
SMMs consisting of 8F20, 10O5, and AN2. Six identical microarrays were printed on 686 
one glass slide and each compound was printed in triplicates in a single microarray. 687 
The printed small SMMs were assembled into a fluidic cartridge with each microarray 688 
housed in a separate chamber. Before the binding reaction, the slide was washed in 689 
situ with a flow of 1× PBS to remove excess unbound samples, followed by blocking 690 
with 7,600 nM BSA in 1× PBS for 30 min. For binding kinetics measurement, 1 × PBS 691 
was first flowed through a reaction chamber at a flow rate of 0.01 mL/min for 5 min to 692 
acquire the baseline. 1 × PBS was then quickly replaced with the probe solution of the 693 
target protein at a flow rate of 2 mL/min for 9 sec followed by a reduced flow rate at 694 
0.01 mL/min to have the microarray incubated in the probe solution under the flow 695 
condition for 35 min (association phase of the reaction). The probe solution was then 696 
quickly replaced with 1 × PBS at a flow rate of 2 mL/min for 9 sec followed by a 697 
reduced flow rate of 0.01 mL/min to allow dissociation of probe for 30 min 698 
(dissociation phase of the reaction). By repeating the binding reactions of the target 699 
protein at three different concentrations on separate fresh microarrays, binding curves 700 
of compounds with the target protein at three concentrations were recorded with 701 
scanning OI-RD microscope. Reaction kinetic rate constants were extracted by fitting 702 
the binding curves globally using 1-to-1 Langmuir reaction mode. 703 
Compound-protein interaction measurements by microscale thermophoresis 704 
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(MST) 705 
The purified recombinant proteins were dialyzed into 1× PBS, and then labelled 706 
according to the protocol of Protein labeling kit RED-NHS (Nanotemper, cat. no. L001). 707 
All the tested stock compounds (10 mM) dissolved in DMSO were also diluted into the 708 
same buffer for the final MST assay. The MST experiment was performed using 709 
Monolith NT.115 instrument (NanoTemper Technologies). 500 nM of labelled proteins 710 
were mixed with the indicated concentrations of candidate compounds in the reaction 711 
buffer containing 20 mM HEPES, pH 7.4, 150 mM NaCl. The MST data were then 712 
collected under 40% infrared laser power and 20% light-emitting diode power. The 713 
data were analyzed by Nanotemper analysis software (1.5.41) and the Kd was 714 
determined. 715 
cDNA plasmids for transfection in mammalian cells 716 
The pEX-GFP-hLC3WT plasmid was obtained from Addgene (#24987) to 717 
express LC3B. The pTT-HTTexon1-Q72-MBP-His and pTT-HTTexon1-Q25-MBP-His 718 
were generated by subcloning HTTexon1 cDNAs into the mammalian expression 719 
vector pTT-MBP-His and then transiently transfected into HeLa cells to express 720 
HTTexon1 proteins for the colocalization experiments. The polyQ-GFP sequences 721 
(expressing Met-polyQ-sfGFP) were de novo synthesized and subcloned into the 722 
pcDNA vector. All plasmids were sequence validated. For transient transfections, the 723 
cells were plated at 50% confluence. After 24 h, the cDNAs were transfected with 724 
Lipofectamine 2000 (ThermoFisher Scientific, cat. no. 11668019) using the forward 725 
transfection protocol provided by the manufacturer.  726 
Cell culture 727 
For mouse primary cortical neuron cultures, cortices were isolated from P0 pups 728 
following genotyping. Cortices were dissected into cold Ca2+- and Mg2+-free PBS 729 
buffer. Chopped small pieces were digested in solution containing 2.5% trypsin 730 
(Sigma, cat. no. P1005) and DNase I (0.1 mg/mL, Sigma, cat. no. D5025), for 20–30 731 
min at 37 °C. Tissues were transferred to 10% FBS containing DMEM (ThermoFisher 732 
Scientific, cat. no. 11965) to cease digestion. Neurons were then dissociated by 733 
trituration with fire-polished glass pipettes, collected by spinning and plated onto 734 
polylysine-coated dishes at 4 × 105 cell/35 mm dish. The growth medium was 735 
composed of Neurobasal A medium (ThermoFisher Scientific, cat. no. 10888022) with 736 
1× B-27 (ThermoFisher Scientific, cat. no. 17504044) and 1× N2 supplement 737 
(ThermoFisher Scientific, cat. no. 17504048). Cytosine-arabinofuranoside (Sigma, 738 
cat. no. C1768) was added at 6 μM to inhibit glial growth. 739 
Some of the primary patient fibroblasts were obtained from HD patients (Q47, 740 
Q49, Q55) and healthy sibling (WT, Q19) controls in a Mongolian Huntington’s 741 
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disease family. The HD Q68 fibroblast line was obtained from Coriell Cell Repositories 742 
(Camden, NJ, USA). The PD line was obtained from an idiopathic Parkinson’s 743 
disease patient, and the SCA3 line was obtained from a SCA3 patient with the ATXN3 744 
expansion mutation (Q74). The studies were approved by The Ethic Community of 745 
Institutes of Biomedical Sciences at Fudan University (#28) for obtaining the HD and 746 
wild-type patient fibroblasts, and by Huashan Hospital Institutional Review Board at 747 
Fudan University (#174) for obtaining the PD and SCA3 patient fibroblasts. Verbal 748 
and written consent was obtained from patients. The procedures were in compliance 749 
with all relevant ethical regulations. The immortalized fibroblasts were generated by 750 
infection of lentivirus expressing SV40T. For generation of iPS cells (iPSCs), the 751 
primary fibroblasts were transduced with the retroviral STEMCCA polycistronic 752 
reprogramming system (Millipore, cat. no. SCR548). The iPSCs were confirmed 753 
positive for Tra-1-81, Tra-1-60, SSEA-4 and Nanog by immunofluorescence and 754 
flow-cytometry. All four vector-encoded transgenes were found to be silenced and the 755 
karyotype was normal. iPSCs were cultured in E8 medium (ThermoFisher Scientific, 756 
cat. no. A1517001) on Matrigel (Corning, cat. no. 354277) surface. iPSCs were 757 
differentiated to Pax6-expressing primitive neuroepithelia (NE) for 10-12 days in a 758 
neural induction medium. Sonic hedgehog (SHH, 200 ng/ml) was added at days 759 
10-25 to induce ventral progenitors. For neuronal differentiation, neural progenitor 760 
clusters were dissociated and placed onto poly-ornithine/laminin-coated coverslips at 761 
day 26 in Neurobasal medium (ThermoFisher Scientific, cat. no. 21103049), with 1× 762 
B-27 (ThermoFisher Scientific, cat. no. 17504044), 1× N-2 (ThermoFisher Scientific, 763 
cat. no. 17504048), brain derived neurotrophic factor (BDNF, 20 ng/ml, Protech, cat. 764 
no. 450-02), glial-derived neurotrophic factor (GDNF, 10 ng/ml, Protech, cat. no. 765 
450-10), insulin-like growth factor 1 (IGF1, 10 ng/ml, Protech, cat. no. 100-11) and 766 
Vitamin C (Sigma cat. no. D-0260, 200 ng/ml). The mouse striatal cells (STHdh) were 767 
obtained from Coriell Cell Repositories (Camden, NJ, USA). The HEK293T cells and 768 
the HeLa cells were originally obtained from American Type Culture Collection 769 
(ATCC). STHdh, HeLa and HEK293T cells were cultured in DMEM (ThermoFisher 770 
Scientific, cat. no. 11965) with 10% (vol/vol) FBS (ThermoFisher Scientific, cat. no. 771 
10082-147). Atg5 WT and KO MEFs were from N. Mizushima. All the mammalian cell 772 
lines were maintained at 37 °C incubator with 5% CO2, except STHdh cells, which 773 
were maintained at 33 °C with 5% CO2. The cells were tested every two months by a 774 
TransDetect PCR Mycroplasma Detection Kit (Transgen Biotech, cat. no. FM311-01) 775 
to ensure that they are mycoplasma free. The CellTiter-glo assay was performed to 776 
measure cell viability with the indicated compound treatment (Extended Data Fig. 2e) 777 
following the protocol provided in the kit (Promega, cat. no. G7570). 778 
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HD Drosophila models 779 
The nervous system driver line elav-GAL4 (c155), and the HTT-expressing lines 780 
UAS-flHTT-Q16 and the UAS-flHTT-Q128 (expressing human full-length HTT with 781 
16Q and 128Q, respectively, when crossed to the GAL4 line) lines were obtained from 782 
the Bloomington Drosophila Stock Center at University of Indiana 783 
(http://flystocks.bio.indiana.edu/), and maintained in a 25 °C incubator. Crosses were 784 
set up between virgin female flies carrying elav-GAL4 driver and the UAS-flHTT-Q16 785 
or UAS-flHTT-Q128 male flies to generate the desired genotypes. 786 
HD mouse models 787 
The generation and characterization of the Hdh140Q knock-in mice have been 788 
previously described19. Mice were group-housed (up to 5 adult mice per cage) in 789 
individually vented cages with a 12 h light/dark cycle. The mouse experiments were 790 
carried out following the ARRIVE (Animal Research: Reporting of In Vivo Experiments) 791 
guidelines, and they were in compliance with all relevant ethical regulations. The 792 
Animal Care and Use Committee of the School of Medicine at Fudan University 793 
approved the protocol used in animal experiments (Approval #20140904 and 794 
#20170223-005).  795 
Compound treatment in cells and animals 796 
The compounds utilized in this study were all commercially available, and quality 797 
controlled by the vendors using NMR. 10O5: GW5074 (DC Chemicals; cat.no. 798 
DC8810); 8F20: ispinesib (Selleck; cat.no. S1452); AN1: 799 
5-bromo-3-[(4-hydroxyphenyl)methylidene]-2,3-dihydro-1H-indol-2-one (Specs; cat. 800 
no. AN-655/15003575); AN2: 5,7-Dihydroxy-4-phenylcoumarin (ChemDiv; cat.no. 801 
D715-2435); GSK923295 (Selleck, cat.no. S7090), BAY1217389 (Selleck, cat.no. 802 
S8215), PLX-4720 (Selleck, cat.no. S1152), Dabrafenib (Selleck, cat.no. S2807), 803 
Sorafenib Tosylate (Selleck, cat.no. S1040), rapamycin (Sigma-Aldrich, cat. no. 804 
R8781). 805 
For compound treatment in the cells, the compounds were diluted in culture 806 
medium to 10X concentrations and added to the plated cells: for primary cultured 807 
neurons and iPSC-derived neurons, the compounds were added 5 days after plating; 808 
for patient fibroblasts and other cell lines, the compounds were added 1 day after 809 
plating. The cells were then collected 2 days later for measurement of HTT levels. For 810 
detection of HTT-LC3 colocalization, the cells were fixed 4 h after compound 811 
treatment. For caspase-3 activation detection, the cells were stressed (BDNF removal 812 
for iPSC-derived neurons) 1 day after compound treatment, and tested at the 813 
indicated time points.  814 
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For compound treatment in the Drosophila, flies were maintained in standard 815 
maize food at 25 °C. For drug feeding, maize media was heated to 45 °C until liquid 816 
and distributed into vials. Compounds were freshly prepared in DMSO and added to 817 
the media. New adult flies were transferred to vials with 400 μL the control (DMSO) or 818 
compound-containing food, which was changed every other day.  819 
For compound treatment in mice using intracerebral ventricular (icv) injection, the 820 
3-month-old mice were anesthetized using a small animal anesthesia machine 821 
(MSS-3, MSS International, Keighley, UK) by Isoflurane (1.5% solution). We surgically 822 
implanted each mouse with a guide cannula directed toward the lateral ventricle. The 823 
coordinates for implantation were determined utilizing “The Mouse Brain in 824 
Stereotaxic Coordinates” and the guide cannulas were placed at 0.6 mm posterior, 825 
1.5 mm lateral (left), and 1.7 mm dorsal with respect to bregma. A cap with stylus was 826 
then inserted into the guide cannula to seal its opening. Mice were then allowed to 827 
recover from surgery for a week before being treated. For injection, we first inserted 828 
an internal injector cannula so that it extended 0.5 mm beyond the tip of the guide 829 
cannula to reach the lateral ventricle. We then injected the mice through the internal 830 
injector cannula using a 25 μL syringe (Hamilton 1700 Series Microliter Syringes , 831 
Bonaduz, GR, CH) at a flow rate of 0.25 µL/min powered by a syringe pump (KDS 832 
Legato 130, Holliston, MA, USA) to administer 2 μL of compounds-containing artificial 833 
cerebrospinal fluid (ACSF: 1 mM glucose, 119 mM NaCl, 2.5 mM KCl, 1.3 mM MgSO4, 834 
2.5 mM CaCl2, 26.2 mM NaHCO3,1 mM NaH2PO4) at a concentration of 25 μM 835 
(containing 0.125% vol/vol DMSO). 2 μL ACSF containing equivalent amount of 836 
DMSO (0.125% vol/vol) was used as the control. The injector cannula was left in 837 
place for approximately 60 s to allow for diffusion before placing the caps with stylus 838 
back in guide cannulas.  839 
For compound treatment in mice using intraperitoneal (ip) injection, each mouse 840 
was weighed. The compounds were diluted with 0.9% NaCl intravenous infusion 841 
solution to 0.05 μg/μL (containing 0.011 μg/μL DMSO) and injected into each mouse 842 
based on the weight of the mouse (500 μg/kg, containing 110 μg/kg DMSO). As 843 
controls, equivalent amount of DMSO was diluted and injected in the same way. 844 
Injection of 0.9% NaCl intravenous infusion solution alone was also tested and 845 
showed no difference (Extended data Fig. 9f-h). One injection per day was performed 846 
for two weeks before subsequent behavioral experiments or tissue extractions.  847 
Note that in some of the experiments (Fig. 4-5 & Extended Data Fig. 6b-d), 8F20 848 
and/or AN1 were not tested. 8F20 was not tested because it did not have an effect in 849 
vivo by icv-injection (Extended Data Fig. 6a). AN1 was not tested because its 850 
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structure is highly similar as 10O5 while it had a weaker HTT-lowering effect by 851 
icv-injection (Extended Data Fig. 6a). 852 
Protein extraction from cells and tissues 853 
For protein extraction from cells, the cell pellets were collected and lysed on ice 854 
for 30 min in 1× PBS+1% Triton X-100+1× complete protease inhibitor (Sigma-Aldrich, 855 
cat. no. 11697498001), sonicated for 10 sec, and spun at >20,000 g at 4 °C for 15 min. 856 
The supernatants were then loaded and transferred onto nitrocellulose membranes 857 
for Western-blots. For mouse brain tissues, the mouse striata and cortices were 858 
dissected on ice and grinded by a tissue grinder for 5 min 60 Hz and lysed on ice for 859 
60 min in brain lysis buffer (50 mM Tris, 250 mM NaCl, 5 mM EDTA, 1% Triton X-100 860 
PH7.4) + 1× complete protease inhibitor (Roche, cat. no. 4693159001). The samples 861 
were then sonicated for 10 cycles, 15 s on and 20 s off, and then collected for 862 
Western-blots.  863 
For protein extraction from the mouse brain, the brains were collected and the 864 
cortices were acutely dissected on ice and homogenized with a tissue grinder for 5 865 
min at 60 Hz and lysed on ice for 60 min in brain lysis buffer (50 mM Tris, 250 mM 866 
NaCl, 5 mM EDTA, 1% (vol/vol) Triton X-100, 1× complete protease inhibitor (Roche, 867 
cat. no. 4693159001), pH=7.4). The samples were then sonicated for 10 cycles, 15 s 868 
on and 20 s off, and then collected for Western-blots, HTRF or dot blots.  869 
For mHTT measurements in the HD Drosophila model, the fly heads were 870 
collected at the age of 7 days and lysed on ice for 30 min in PBS + 1% (vol/vol) Triton 871 
X-100 + 1× complete protease inhibitor (Roche, cat. no. 4693159001), sonicated for 872 
10 cycles, 15 s on and 20 s off, and then collected for HTRF.  873 
For all the samples, the protein concentrations were measured to correct the 874 
loadings. Different protein concentrations or cell numbers per well were tested to 875 
ensure that the signals were in the linear range. Background corrections were 876 
performed by subtracting the background signals from blank samples. 877 
Western-blot and filter trap assays 878 
For Western-blots, the samples were loaded onto the SDS page gel (5-12% 879 
depending on the molecular weight of the protein of interest). The proteins on the gel 880 
were then transferred to the nitrocellulose membranes for blocking and antibody 881 
detection. The signal was detected with ECL (Bio-Rad, cat. no. 1705061) after 1 h 882 
incubation of the membrane with secondary antibody 1:10,000. 883 
The filter trap assay was performed similarly as previously described23, 2 μL (10 884 
μg) aliquots of each sample were loaded onto nitrocellulose membranes stacked in 885 
the Bio-Dot microfiltration apparatus (Bio-Rad). The membrane was blocked for 1 h 886 
with 5% milk and incubated overnight with the antibody 4C9 at a concentration of 1.5 887 
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μg/μl in 5% milk diluted in PBS + 0.1% Tween-20. The signal was detected with ECL 888 
(Bio-Rad, cat. no. 1705061) after 1 h incubation of the membrane with secondary 889 
antibody 1:10,000. 890 
Homogeneous Time Resolved Fluorescence (HTRF) assays 891 
For HTRF, the assays were similar as previously described25. The cell or tissue 892 
lysates were diluted with the original lysis buffer PBS + 1% (vol/vol) Triton X-100 + 1× 893 
complete protease inhibitor (Roche), utilized for lysing the samples, and then detected 894 
with indicated antibody pairs diluted in the HTRF assay buffer (50 mM NaH2PO4, 400 895 
mM NaF, 0.1% BSA, 0.05% (vol/vol) Tween-20, 1% (vol/vol) Triton X-100, pH 7.4). 896 
The donor antibody concentration was 0.023 ng/μL and the acceptor antibody 897 
concentration was 1.4 ng/μL, both in HTRF assay buffer. Different antibody pairs were 898 
used for different experiments as indicated in the figure legends. For all the samples, 899 
the signals were normalized to the total protein concentrations to ensure equal 900 
loadings. Different protein concentrations were pre-tested to ensure that the signals 901 
were in the linear range. Background corrections were performed by subtracting the 902 
background signals from blank samples. 903 
In vitro c-Raf kinase assay 904 
In vitro c-Raf kinase assays were carried out with a c-Raf kinase assay kit (BPS 905 
Bioscience, cat. no. 79570). The assays were performed in a 96-well plate according 906 
to the manufacturing instruction. The samples and non-reactive negative controls 907 
were tested in duplicate according to the instruction. 908 
For details, 25 µL of the mixture containing 5x kinase assay buffer (6 µL), ATP (1 µL), 909 
5x Raf substrate (10 µL) and water (8 µL) was added to a well. 5 µL of water solution 910 
containing a test compound at a 10x desired concentration (DMSO was at 10% at the 911 
water solution) was added to the 25 µL of mixture, and 20 µL of 1x kinase assay 912 
buffer containing 2 ng/µL c-Raf kinase was added to the mixture in a well to initiate the 913 
kinase reaction (at this stage compounds were at 1x desired concentration, and 914 
DMSO was at 1% concentration). For a non-reactive negative control, 20 µL of 1x 915 
kinase assay buffer containing no c-Raf was added to the mixture instead. The plate 916 
was incubated at 30 °C for 45 min. After the 45-min reaction, 50 µL of kinase 917 
Kinase-Glo Max reagent (Promega, cat. no. V6071) was added to each well, and the 918 
plate was incubated at room temperature for 15 min, at dark. The plate was read with 919 
a microplate reader (BMG Labtech) for luminescence reading. The luminescence 920 
reading value measures the levels of ATP remaining, which is inversely related to 921 
kinase activity. The non-reactive negative control read value, indicating the level of 922 
initial added ATP, subtracted the level of ATP remaining (the luminescence reading) 923 
for the value of consumed ATP in the reaction that represents a kinase activity. 924 
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In vitro pull-down assays 925 
We performed in vitro pull-down assays to test the compounds’ influence on the 926 
HTT-LC3 interactions. The purified HTTexon1 (with the indicated tags), full-length 927 
proteins and the control proteins were incubated with amylose resin (New England 928 
BioLabs, cat. no. E8021L) at 4 °C for 30min. Immobilized amylose resins were then 929 
washed three times with HBS (20 mM HEPES pH7.5, 150 mM NaCl, 0.05% 930 
Tween-20). The resulting amylose resins containing about 10 μg of MBP-fused 931 
proteins were incubated with the indicated compounds (1 μM for 10O5 and 100 nM for 932 
AN2) or the DMSO control at the same volume in 300 μl of HBS at 4 °C for 1 h using 933 
sample mixer. 40 μg of purified LC3B protein were then added and incubated at 4 °C 934 
for another 2 h using sample mixer. The resin-bound proteins were eluted with 40 μl 935 
maltose buffer (10 mM maltose, 20 mM HEPES, 150 mM NaCl, pH 7.5) and then 936 
added with 20 μl SDS-PAGE sample loading buffer. Samples were then analyzed by 937 
SDS-PAGE and Western-blots. 938 
GST pulldown was performed as the same procedures described above, except 939 
that GST-fused LC3B was immobilized onto magnetic conjugated GST mouse mAb 940 
beads (Cell Signaling Technology, cat.no.11847S) and eluted with SDS-PAGE 941 
protein loading buffer by vortex according to the instruction manual. 942 
Imaging-based autophagy assays  943 
Analysis of GFP-LC3 puncta for measuring autophagosomes: HeLa cells stably 944 
expressing GFP-LC3 were generated by transfection of pEGFP C1-LC3, and positive 945 
clones were selected by 500 μg/ml G418. The cells were then treated with vehicle 946 
(DMSO, 0.1%), 10O5, or AN2 for the indicated concentration, chloroquine (CQ, 20 947 
μM) treatment was used as a control. After 24 hours, cells were fixed in 4% 948 
paraformaldehyde (PFA) for 10 min. Images were acquired with confocal microscopy 949 
(Leica SP8) by the observer blinded to the identity of the slides. The number and size 950 
of GFP vesicles per cell was determined by Image J software. Images were 951 
processed with the despeckle function to decrease the noise, and a threshold was set 952 
to highlight puncta. Cells were selected by the freehand drawing tool. The 953 
analyze-particle function was used for the sizes and numbers of GFP puncta. 954 
The mRFP-GFP-LC3 assay: this assay allows us to monitor autophagosome 955 
synthesis and maturation/fusion by labelling autophagosomes (green and red) and 956 
autolysosomes (red), since the low lysosomal pH in autolysosomes quenches the 957 
GFP signals32. HeLa cells stably expressing mRFP-GFP-LC332 were treated with 958 
vehicle (DMSO, 0.1%), 10O5, or AN2 for the indicated concentration, bafilomycin-A1 959 
(bafA1, 10 nM) treatment was used as a control. After 24 hours, cells were fixed in 4% 960 
PFA for 10 min. Images were acquired with confocal microscopy (Leica SP8) by the 961 
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observer blinded to the identity of the slides. The green and red single channel 962 
images were analyzed by Image J to quantify green and red puncta in the same way 963 
as in the GFP-LC3 assay described above.  964 
Detection of long-lived proteins by click-chemistry 965 
As an indicator of autophagy activity, the degradation of long-lived proteins was 966 
measured similarly as previously reported33. Basically, the HeLa cells with 70~80% 967 
confluency in a 6-well plate were washed with warm PBS and cultured in Met-free 968 
DMEM (ThermoFisher Scientific, cat. no.21013) added with dialyzed FBS for 1 h to 969 
deplete intracellular free Met reserves. The Met analog L-AHA (50 µM) was then 970 
added to label the proteins for 18 h. After labeling, the cells were washed with PBS 971 
and cultured in regular culture medium containing 10x L-Met (2 mM) for 2 h to chase 972 
out short-lived proteins. The cells were then treated with the compounds versus the 973 
DMSO controls for 6 h before cell lysis and protein extraction. For the starvation 974 
sample, the culture medium was replaced with EBSS (ThermoFisher Scientific, cat. 975 
no. 24010043) for 6 h. The protein lysates were then used for the click reaction by the 976 
Click-it reaction kit (Click Chemistry tools, cat. no. C1001) following manufacturer’s 977 
instructions, and the remaining L-AHA containing long-lived proteins were then 978 
conjugated with biotin. These proteins were then analyzed by electrophoresis and 979 
detected by the HRP-conjugated streptavidin (Beyotime, cat. no. A0303).  980 
Immunofluorescence and caspase-3 imaging 981 
For immunofluorescence of cultured cells, cells were fixed in 4% PFA for 10 min 982 
after washing with 1× PBS for three times, and then washing and permeabilized in 0.5% 983 
(vol/vol) TritonX-100 for 10 min. The cells were then blocked in blocking buffer (4% 984 
BSA + 0.1% (vol/vol) Triton X-100 in 1× PBS) for 30 min and incubated overnight at 985 
4 °C with primary antibodies, and then washed three times with blocking buffer and 986 
incubated with secondary antibody at room temperature for 1 h. Coverslips were then 987 
washed three times, stained with 0.5 mg/ml DAPI for 5 min at room temperature, and 988 
then mounted in vectashield mounting medium (Vector, cat.no. H-1002). Images were 989 
taken by Zeiss Axio Vert A1 confocal microscopes and analyzed blindly by ImageJ for 990 
co-localization and TUBB3 quantifications. For co-localization experiments of 991 
transfected HeLa cells (Fig. 4c), the GFP signals were used to detect GFP-LC3B, and 992 
anti-His was used to detect HTTexon1-MBP-His proteins. Empty vector transfected 993 
cells were imaged to ensure the specificity of the signals. The co-localization was 994 
analyzed by calculating the ratio between overlapping puncta and the HTT (red) 995 
puncta for each cell, and the puncta numbers were counted blindly. For co-localization 996 
experiments of STHdhQ111/Q111 cells, the endogenous mHTT protein was stained with 997 
the HTT antibody (Millipore, cat. no. MAB2166), and autophagosomes were stained 998 
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with the LC3B antibody (ThermoFisher Scientific, cat. no. 700712), which 999 
preferentially detects LC3-II38. The co-localization was analyzed by ImageJ to 1000 
calculate the ratio between overlapping pixels and the HTT (red) positive pixels, 1001 
because the signals of the endogenous proteins were more dispersed and could not 1002 
be counted accurately. For TUBB3, the total area of TUBB3 signals and the DAPI 1003 
counts were analyzed by ImageJ. The former is then divided by the latter to calculate 1004 
the averaged area of TUBB3 in each neuron as an index for neurodegeneration in 1005 
vitro.  1006 
For caspase-3 activity measurements of the iPSC-derived neurons, the NucView 1007 
488 caspase-3 dye (Biotium, cat. no. 30029) was used for the caspase 3 activity 1008 
detection as an indicator for apoptosis. The images were then taken every 3 h using 1009 
the Incucyte technology (Essen Bioscience, IncuCyte FLR), which takes images of 4 1010 
different fields in each well inside the cell culture incubator. The quantification was 1011 
performed by the Incucyte 2011A software, which identified the green fluorescent 1012 
puncta and quantified the fluorescent object count per field. The 4 fields per well were 1013 
quantified and averaged, and 4 independent wells were used for statistical analysis. 1014 
Antibodies 1015 
Antibodies used for Western-blots, HTRF and/or 1016 
immunofluorescence/immunohistochemistry are as follows: the HTT antibodies 2B739, 1017 
ab140 and MW141 have been described previously; commercially purchased 1018 
antibodies include HTT antibody 2166 (Millipore, cat. no. MAB2166), anti-polyQ 1019 
antibody 3B5H10 (Sigma, cat. no. P1874), anti-HTT antibody (D7F7)XP (Cell 1020 
Signaling Technologies, cat. no. 5656s), anti-β-tubulin (Abcam, cat. no. ab6046), 1021 
anti-TUBB3 (Biolegends (previously Covance), cat. no. 801202), anti-ATXN3 1022 
(Millipore, cat. no. MAB5360); anti-Gapdh (Proteintech, cat. no. 60004-1), anti-NBR1 1023 
(ThermoFisher Scientific, cat. no. PA5-54660), anti-β-actin (Beyotime, cat. no. 1024 
AA128); anti-TBP (Abcam, cat. no. ab818); anti-P62 (ThermoFisher Scientific, cat. no. 1025 
PA5-27247); anti-spectrin (Millipore, cat. no. MAB1622); anti-Ncoa4 (Santa cruz, 1026 
cat.no. sc-373739); anti-GST (ProteinTech, cat. no. HRP-66001); anti-GFP (Cell 1027 
Signaling Technologies, cat. no. 2956); anti-MBP (ProteinTech, cat. no. 15089-1-AP); 1028 
anti-His (Beyotime, cat. no. AH367); anti-BUBR1 (BD Transduction, cat.no, 612503); 1029 
anti-phospho-p44/42 MAPK (ERK1/2) and anti-phospho-MEK1/2 in the 1030 
Phospho-Erk1/2 Pathway Sampler Kit (Cell Signaling Technology, cat.no. 9911); 1031 
anti-LC3B (ThermoFisher Scientific, cat.no. PA1-16930 (for Western-blot) & cat. no. 1032 
700712 (for immunofluorescence)). All the antibodies used for immunofluorescence in 1033 
this study have been validated by knock-down experiments. All the HTT, polyQ and 1034 
ATXN3 antibodies used for HTRF and/or Western-blots have been validated by 1035 
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knock-down experiments and by comparing the signals from different genotypes in 1036 
previous studies from us and others. All the other antibodies have been validated by 1037 
previous literature or the vendor.  1038 
Compound detection in vivo in brain tissue from ip-injected mice 1039 
The experiments were performed by the SIM-Servier joint laboratory. The mice 1040 
ip-injected with DMSO or the indicated compounds were anesthetized by chloral 1041 
hydrate (200 μL/kg of 10% stock) at indicated time points, and the heart blood was 1042 
collected by vacuum blood collection tubes. The heart blood samples were further 1043 
spun at 10,000 rpm for 5 min to generate the heart plasma. The mice were then 1044 
perfused with 1X PBS to remove the blood. The mice were then sacrificed and the 1045 
brain samples were dissected. 5 times of volume of methanol: acetonitrile (50: 50, 1046 
vol/vol) were added to each sample, which was then homogenized. Following 1047 
ultrasonic treatment for 15 min, the homogenates were centrifuged for 5 min, then 20 1048 
μL supernatant liquid was mixed with 20 μL water for 30s before injection. Linear 1049 
range of 10O5 was 10-30000 ng/mL, and the linear range of AN2 was 0.3-10000 1050 
ng/mL. The LC-MS/MS analyses were performed on an Acquity ultra performance 1051 
liquid chromatography (UPLC) system (Waters Corporation, Milford, MA, USA) 1052 
coupled to a Xevo TQ-S mass spectrometer (Waters Corporation, Milford, MA, USA). 1053 
Chromatographic separation was performed using an Acquity UPLC BEH C18 (1.7 1054 
μm 2.1 × 50 mm) column supplied by Waters at a flow of 0.5 mL/min. Gradient elution 1055 
was used with a mobile phase composed of solvent A (water containing 0.1% formic 1056 
acid and 5 mM NH4AC) and solvent B (acetonitrile: methanol (9:1,vol/vol) containing 1057 
0.1% formic acid). 1058 
Proteomics analysis 1059 
Samples were analyzed on Orbitrap Fusion Lumos mass spectrometers (Thermo 1060 
Fisher Scientific, Rockford, IL, USA) coupled with an Easy-nLC 1000 nanoflow LC 1061 
system (Thermo Fisher Scientific). Dried peptide samples were re-dissolved in 1062 
Solvent A (0.1% formic acid in water) and loaded to a trap column (100 μm×2 cm; 1063 
particle size, 3 μm; pore size, 120 Å; SunChrom, USA) with a max pressure of 280 bar 1064 
using Solvent A, then separated on a 150 μm×15 cm silica microcolumn (particle size, 1065 
1.9 μm; pore size, 120 Å; SunChrom, USA) with a gradient of 5–35% mobile phase B 1066 
(acetonitrile and 0.1% formic acid) at a flow rate of 600 nL/min for 75min. The FAIMS 1067 
device was placed before the mass spectrometer. FAIMS separation was performed 1068 
with the following settings: inner electrode temperature = 100 °C, outer electrode 1069 
temperature = 100 °C, carrier gas flow= 4.6 L/min, Dispersion Voltage = −5000 V, 1070 
entrance plate voltage = 250 V. The FAIMS carrier gas is N2 only. The noted CVs were 1071 
applied to the FAIMS electrodes. Each of the selected CVs was applied to sequential 1072 
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survey scans and MS/MS cycles (1s); the MS/MS CV was always paired with the 1073 
appropriate CV from the corresponding survey scan. For detection with Fusion or 1074 
Fusion Lumos mass spectrometry, a precursor scan was carried out in the Orbitrap by 1075 
scanning m/z 300−1400 with a resolution of 120,000. The most intense ions selected 1076 
under top-speed mode were isolated in Quadrupole with a 1.6m/z window and 1077 
fragmented by higher energy collisional dissociation (HCD) with normalized collision 1078 
energy of 30%, then measured in the linear ion trap using the rapid ion trap scan rate. 1079 
Automatic gain control targets were 5×105 ions with a max injection time of 50 ms for 1080 
full scans and 1×104 with 35 ms for MS/MS scans. Dynamic exclusion time was set at 1081 
18 s. Data were acquired using the Xcalibur software (Thermo Scientific). 1082 
Rawfiles were searched against the human National Center for Biotechnology 1083 
Information (NCBI) Refseq protein database (updated on 04-07-2013, 32,015 entries) 1084 
by Mascot 2.3 (Matrix Science) implemented on Proteome Discoverer 2.2 (Thermo 1085 
Scientific). The mass tolerances were 20 ppm for precursor and 0.5 Da for product 1086 
ions for Fusion Lumos. Up to two missed cleavages were allowed. The search engine 1087 
set cysteine carbamidomethylation as a fixed modification and N-acetylation, 1088 
oxidation of methionine as variable modifications. Precursor ion score charges were 1089 
limited to +2, +3, and +4. The data were also searched against a decoy database so 1090 
that protein identifications were accepted at a false discovery rate of 1%. Label-free 1091 
protein quantifications were calculated using a label-free, intensity-based absolute 1092 
quantification (iBAQ) approach. 1093 
Proteins with at least 2 unique peptides with 1% FDR at the peptide level and 1094 
Mascot ion score greater than 20 were selected for further analysis. The file used for 1095 
protein inference and protein FDR calculation was derived from Mascot search results, 1096 
and the peptide spectrum match (PSM) was filtered via Percolator and customized 1097 
parameters, and then the proteins were assembled. The protein FDR was calculated 1098 
depending on the ratio of NPD (the number of assembled proteins from decoy 1099 
database searches) and NPT (the number of assembled proteins from target 1100 
database searches). The FOT was used to represent the normalized abundance of a 1101 
particular protein across samples. FOT was defined as a protein’s iBAQ divided by the 1102 
total iBAQ of all identified proteins within one sample. The FOT was multiplied by 105 1103 
for the ease of presentation. Only the proteins detection in all compared samples 1104 
were utilized for comparison. 1105 
Behavioral and lifespan experiments in HD Drosophila models 1106 
For behavioral experiments, we placed 15 age-matched virgin female flies in an 1107 
empty vial and tapped them down. The percentage of flies that climbed past a 1108 
7-cm-high line after 15 s was recorded. The mean of five observations is plotted for 1109 
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each vial on each day, and data from multiple vials containing different batches of flies 1110 
were plotted and analyzed by two-way ANOVA tests. The flies were randomly placed 1111 
into each tube. For lifespan measurements, we placed 75 age-matched virgin female 1112 
flies in an empty plastic vial and recorded the survival situation for each vial on each 1113 
day. For both behavioral and lifespan measurement experiments, the person who 1114 
performed the experiments were blinded to the drugs fed until data analysis. 1115 
Behavioral experiments in HD mouse models 1116 
All the behavioral experiments were performed during the light phase and the 1117 
experimenters were blinded to the compound treatment and the genotype of each 1118 
mouse. Both males and females have been used. All the mice were kept in the 1119 
behavioral test room in dim red light for 1 h before starting the experiments. For 1120 
rotarod experiments, mice were pre-trained on 3 consecutive days on the rotarod 1121 
rotating at 4 rpm for 2 min. Mice were then tested for five days at an accelerating 1122 
speed ranging from 4 to 40 rpm within 2 min. Each performance was recorded as the 1123 
time in seconds spent on the rotating rod until falling off or until the end of the task. 1124 
Each test included three repetitions with an inter-trial interval of 60 min in order to 1125 
reduce stress and fatigue, and the means from these three runs were analyzed for 1126 
each mouse. The balance beam test was run using a 2 cm thick meter stick 1127 
suspended from a platform on both sides by metal grips. The total length is 100 cm. 1128 
There was a bright light at the starting point and a dark box with food at the endpoint. 1129 
The total time for each mouse to walk through the bean was recorded. For gripping 1130 
force measurements, mice were allowed to grip the metal grids of a grip meter 1131 
(Ametek Chatillon) with their forelimbs, and they were gently pulled backwards by the 1132 
tail until they could no longer hold the grids. The peak grip strength observed in 10 1133 
trials was recorded. 1134 
Statistics 1135 
    To ensure to reach a statistical power>0.8, power analyses were performed for 1136 
each assay based on estimated values by PASS 16 1137 
(https://www.ncss.com/software/pass/) before experiments. Estimation was based on 1138 
our previously published results on similar experiments and preliminary experiments. 1139 
The effect size was also estimated by Cohen's d, two means divided by the standard 1140 
deviation for the data. The power analysis suggested n > 3 for mHTT level 1141 
measurements and n > 5 for behavioral experiments. In all the experiments we 1142 
performed, we have used a larger n than these numbers in case the effect was 1143 
smaller than preliminary results, and we also performed post-experiment power 1144 
analyses to ensure that power > 0.8 for all the significant differences. Statistical 1145 
comparisons between two groups were conducted by the unpaired two-tailed t tests. 1146 
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Statistical comparisons among multiple groups were conducted by one-way ANOVA 1147 
tests and post-hoc tests for the indicated comparisons (Dunnett’s tests for comparison 1148 
with a single control, and Bonferroni’s tests for comparisons among different groups). 1149 
Statistical comparisons for series of data collected at different time points were 1150 
conducted by two-way ANOVA tests. The similarity of variances between groups to be 1151 
compared was tested when performing statistics in GraphPad Prism 7 and Microsoft 1152 
Excel 2016. Normality of data sets was assumed for ANOVA and t tests, and was 1153 
tested by Shapiro-Wilk tests. When the data were significantly different from normal 1154 
distribution, nonparametric tests were used for statistical analysis. All statistical tests 1155 
were unpaired and two-tailed. 1156 
 1157 
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 1218 
Extended data figure/table legends 1219 
Extended Data Fig. 1. Protein purifications. 1220 
a) SDS-PAGE and linear mode MALDI-TOF mass spectrometry analysis of the 1221 
expression and purification of recombinant LC3B protein. For SDS-PAGE, lane 1, the 1222 
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whole cell lysate before induction; lane 2, the whole cell lysate after induction; lane 3, the 1223 
supernatants of induced cells; lane 4, the flow through fraction of Ni-NTA chromatography; 1224 
lane 5, the eluates of Ni-NTA chromatography (GST-His8-LC3); lane 6, the eluates of 1225 
GST-His8 tag removed LC3B by TEV protease; lane 7, the eluates of size exclusive 1226 
chromatography; lane 8, molecular weight marker. The obtained mass spectrometry m/z 1227 
peak of recombinant LC3B is 14660.811, consistent with theoretical calculations 1228 
b) Structural alignment of purified recombinant LC3B∆G120 (PDB: 6J04, yellow) with 1229 
published LC3B structure (PDB: 1UGM, cyan) by Pymol.  1230 
c-d) SDS-PAGE and linear mode MALDI-TOF mass spectrometry analysis of the 1231 
HTTexon1 proteins. For HTTexon1-Q72-MBP SDS-PAGE, lane 1, the supernatants of 1232 
induced cells; lane 2, the insoluble fraction of induced cells; lane 3, the flow through 1233 
fraction of Ni-NTA chromatography; lane 4, the eluates of Ni-NTA chromatography; lane 5, 1234 
the eluates of size exclusive chromatography; lane 6, molecular weight marker. For 1235 
HTTexon1-Q25-MBP SDS-PAGE, lane 1, molecular weight marker; lane 2, the induced 1236 
cell lysate; lane 3, the supernatant fraction of induced cells; lane 4, the flow through 1237 
fraction of Ni-NTA chromatography; lane 5 and 6, the eluates of Ni-NTA chromatography; 1238 
lane 7 and 8, the eluates of size exclusive chromatography. The obtained mass 1239 
spectrometry m/z peak of HTTexon1-Q72-MBP and HTTexon1-Q25-MBP are 64225.946 1240 
and 58228.893, consistent with theoretical calculations.  1241 
e) Left and middle panels: size exclusive chromatography of the recombinant full-length 1242 
HTT-Q73 (flHTT-Q73) and HTT-Q23 (flHTT-Q23) proteins using Superose 6 5/150 GL. 1243 
The major peak fractions were then collected pooled together for the SDS-PAGE analysis 1244 
(right panel). 1245 
f) SDS-PAGE analysis of purified MBP-His8 (MBP), sfGFP (GFP), and Rpn10 proteins. 1246 
 1247 
Extended Data Fig. 2. Negative controls for OI-RD measurements and validation of 1248 
the compounds’ interaction with HTT and LC3 by MST. 1249 
a) Similar to Fig. 1c-e, but for negative control proteins MBP-His8 (MBP), superfolder GFP 1250 
(sfGFP), and ubiquitinated-Rpn10 (Ub-Rpn10). Association-dissociation curves of surface 1251 
immobilized compounds 8F20 and 10O5 with these proteins were measured by OI-RD, 1252 
and no compound-protein interactions were detected. For all association-dissociation 1253 
curves, vertical dash lines mark the starts of association and dissociation phases of the 1254 
binding event.  1255 
b) Binding of 10O5 and 8F20 to full-length HTT-Q73 (flHTT-Q73, black dots) or LC3B (red 1256 
dots) in standard treated capillaries measured by MST. The compound bound protein 1257 
fractions (bound / total) were calculated by the MST signals (Fnorm) at each compound 1258 
concentrations, as well as the bound (Fnorm_bound, set as 100%) and the unbound 1259 
(Fnorm_unbound, set as 0%) MST signals: bound / total = (Fnorm – Fnorm_unbound) / (Fnorm_bound – 1260 
Fnorm_unbound) x 100%. The fitted curves and calculated Kd values by the Nanotemper 1261 
analysis software (1.5.41) for flHTT-Q73 and LC3B were indicated in each panel. 1262 
Consistent with the OI-RD measurements (Fig. 1e), no binding was observed for the 1263 
flHTT-Q23 protein (blue dots). The MST experiments were repeated > 3 times and 1264 
showed consistent results. 1265 
c) Similar to b), except testing the compounds indicated in the X-axis. MST measurements 1266 
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of the binding of indicated compounds to full-length HTT-Q73 (flHTT-Q73), full-length 1267 
HTT-Q23 (flHTT-Q23) and LC3B in standard treated capillaries. The proteins tested were 1268 
indicated in the legends.  1269 
d) Similar to Fig. 1c-e, but plotting the association-dissociation curves of surface 1270 
immobilized compound AN2 with full-length HTT-Q73 (Q73), or full-length HTT-Q23 (Q23), 1271 
or LC3B, or the negative control proteins MBP-His8 (MBP), superfolder GFP (sfGFP), and 1272 
Rpn10.  1273 
For all association-dissociation curves, vertical dash lines mark the starts of association 1274 
and dissociation phases of the binding event. The red dash lines are global fits to a 1275 
Langmuir reaction model with the global fitting parameters listed at the bottom of each plot. 1276 
No binding signals were observed for full-length HTT-Q23 proteins, and thus the 1277 
parameters were not presented. 1278 
e) Cell viability measurement of cultured HD neurons measured by the CellTiter-glo assay. 1279 
No toxicity was observed within the concentration range presented in Fig. 2, although the 1280 
compound 8F20 became toxic to the cells when the concentration reached 300 nM. 1281 
 1282 
Extended Data Fig. 3. mHTT lowering effects by mHTT-linker compounds could be 1283 
detected by multiple antibodies and were dependent on autophagy. 1284 
a) Representative Western-blots (HTT detected by the 2166 antibody) and quantifications 1285 
of compound-treated cultured cortical neurons from HdhQ7/Q140 HD knockin mice. The 1286 
neurons were treated with the indicated compounds (100 nM for 10O5, 8F20 and AN1; 50 1287 
nM for AN2) with or without the autophagy inhibitor NH4Cl (upper panels) or chloroquine 1288 
(lower left), or the autophagy activator rapamycin (lower right). Same amount of culture 1289 
medium was added in the controls (upper panels). The statistical analysis was performed 1290 
by one-way ANOVA with post-hoc Dunnett’s tests, and the F/degree of freedom/post-hoc 1291 
p values have been indicated in each bar plot.  1292 
b) Western-blots using indicated HTT/polyQ antibodies for samples from cultured cortical 1293 
neurons treated with the indicated compounds: 10O5 (100 nM), 8F20 (100 nM), AN2 (50 1294 
nM). The HTT gel blots presented in Fig. 2d (right panel) were cropped from first four blots. 1295 
The low molecular weight bands were run out in these blots so that the wtHTT and mHTT 1296 
could be better separated. Note that the weak bands just above 250 kDa in the first two 1297 
blots were leftover signals from the Spectrin blotting. The Spectrin signals were too strong 1298 
to be stripped completely. 1299 
c) Western-blots using the antibody MW1 or 3B5H10 that detects mHTT specifically. The 1300 
relatively low molecular weight proteins were kept. No increase of potential 1301 
polyQ-containing mHTT N-terminal fragments was observed. 1302 
d) HD patient iPSC-derived striatal neurons (Q47) were treated with the indicated 1303 
compounds (100 nM, with 0.1% DMSO) in presence of an additional 0.1% DMSO or 10 1304 
mM NH4Cl, and the mHTT levels were measured by HTRF using the 2B7/MW1 antibody 1305 
pair. All signals were normalized to the averaged signals from the DMSO control group. 1306 
The statistical analysis was performed by one-way ANOVA with post-hoc Dunnett’s tests, 1307 
and the F/degree of freedom/post-hoc p values have been indicated in each bar plot. “****”: 1308 
p<0.0001. The post-hoc analysis was not performed if the ANOVA tests did not show 1309 
significance (p>0.05).  1310 
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e) The HD patient immortalized fibroblasts (Q47) were transfected with the non-targeting 1311 
control siRNA (Neg siRNA) or the ATG5 siRNA (target sequence: 1312 
GCCUGUAUGUACUGCUUUA; ATG5 mRNA was knocked down to 17.7 ± 3.0%, n =3, as 1313 
tested by qPCR), and then after 24 hours treated with the indicated compounds (100 nM) 1314 
for another 48 hours. mHTT levels were then measured by HTRF using the 2B7/MW1 1315 
antibody pair. All signals were normalized to the averaged signals from the DMSO control 1316 
group. The statistical analysis was performed by one-way ANOVA with post-hoc Dunnett’s 1317 
tests, and the F/degree of freedom/post-hoc p values have been indicated in each bar plot. 1318 
“****”: p<0.0001. The post-hoc analysis was not performed if the ANOVA tests did not 1319 
show significance. The Western-blot of LC3 confirmed the partial inhibition of autophagy 1320 
in the ATG5 knockdown cells. 1321 
f) Similar to e), but in wild-type (WT) or Atg5 knockout (Atg5 KO) mouse embryonic 1322 
fibroblast lines (MEF) transfected with full-length mHTT (flHTT-Q73). The Western-blot of 1323 
LC3 confirmed the inhibition of autophagy in the Atg5 KO cells. 1324 
For all panels, n indicates the number of independently plated wells, and bars represent 1325 
mean and s.e.m.. Full-blots of cropped gels are shown in Supplementary Fig. 1. 1326 
 1327 
Extended Data Fig. 4. Potential influence of c-Raf and KSP pathways by treatment 1328 
of the mHTT-LC3 linker compounds. 1329 
a) Representative results (from 3 biological repeats) of the in vitro c-Raf kinase assay (see 1330 
“Methods”) showing that only 10O5 inhibits c-Raf activity within the concentration range 1331 
tested.  1332 
b) Representative Western-blots and quantifications of phospho-MEK/ERK as an indicator 1333 
of Raf activities (left) and phospho-Bubr1 as an indicator of KSP inhibition (right) in 1334 
cultured cortical neurons treated with indicated compounds (100 nM for 10O5, 8F20, AN1, 1335 
and 50 nM for AN2) or the DMSO control. 1336 
c) Similar to b), but in immortalized HD patient fibroblasts (Q47). Note that the 1337 
phospho-Bubr1 is essentially absent and too weak to quantify, indicating that KSP was not 1338 
inhibited by any of the compounds at the concentration tested. 1339 
For all panels, error bars represent mean and s.e.m.. For b, all data were corrected by the 1340 
loading control (β-Tubulin) and then normalized to the averaged signal of the DMSO 1341 
control group. The statistical analysis was performed by one-way ANOVA and the 1342 
F/degree of freedom/p values have been indicated in each bar plot. The n number 1343 
indicates the number of independently plated and treated wells. 1344 
 1345 
Extended Data Fig. 5. mHTT-LC3 linker compounds lowered mHTT in transgenic HD 1346 
flies. 1347 
a) Overlay between LC3B and predicted Atg8 structure showing high structural similarities. 1348 
b) Transgenic flies expressing full-length HTT-Q128 driven by elav-GAL4 were fed with 1349 
indicated compounds at 10 μM for 6 days, and their heads were then extracted for protein 1350 
lysates. mHTT were then measured by HTRF using the 2B7/MW1 antibody pair. 1351 
Each dot represents the HTRF signal from each individual sample extracted from 5 fly 1352 
heads. All the data were normalized to the average of the DMSO-fed control samples. The 1353 
statistical analysis was performed by one-way ANOVA and Dunnett’s post hoc tests. F (4, 1354 
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31) = 15.67; “****”: p<0.0001. 1355 
c) 10O5 (upper panel) and AN2 (lower panel) concentrations in heart plasma and brain 1356 
tissues were measured by mass-spectrum at indicated time points for compound-injected 1357 
mice (0.5 mg/kg). In the brain tissue, the 10O5 concentrations were ~20 to ~200 nM, and 1358 
the AN2 concentrations were ~20 to ~40 nM, close to the effective doses that were 1359 
capable of lowering mHTT in cultured neurons. Data were plotted by mean and s.e.m..  1360 
 1361 
Extended Data Fig. 6. mHTT-LC3 linker compounds lowered mHTT in vivo in the 1362 
mouse brains. 1363 
a) Western-blots (4 mice (3 months old) for each group) and quantifications of mHTT and 1364 
wtHTT in the cortices from HdhQ7/Q140 knockin mice icv-injected with the indicated 1365 
compounds (2 μL at 25 μM for each mouse) for 10 days at one-dose per day. HTT were 1366 
detected by Western-blots using the 2166 antibody, and the statistical analysis was 1367 
performed by one-way ANOVA and post-hoc Dunnett’s tests. The F/degree of 1368 
freedom/post-hoc p values have been indicated under each bar plot.  1369 
b) Similar to a), except that the compounds were delivered by ip-injection (0.5 mg/kg) to 1370 
HdhQ7/Q140 mice at 5 months-old for 14 days at one-dose per day.  1371 
c) Similar to b), but from striata of ip-injected mice. The mice were injected at 10 1372 
months-old for 14 days at one-dose per day. 1373 
d) Left panel: representative dot-blot results (from two technical replicates) of the protein 1374 
lysates in b) using the 4C9 antibody, which preferentially detects mHTT aggregates23. 1375 
Middle panel: quantification of the dot-blots based on the averaged signals from two 1376 
technical replicates. Right panel: measurement of mHTT aggregates by the 4C9/4C9 1377 
HTRF assay23.  1378 
For all panels, n indicates the number of mice tested, and bars represent mean and s.e.m.. 1379 
For quantification, two to three technical replicates were averaged for each mouse. The 1380 
statistical analysis was performed by one-way ANOVA with post-hoc Dunnett’s tests, and 1381 
the F/degree of freedom/post-hoc p values have been indicated in each bar plot. 1382 
 1383 
Extended Data Fig. 7. mHTT-LC3 linker compounds did not influence autophagy. 1384 
a) HeLa cells stably expressing GFP-LC3B were treated with 2 μl vehicle (0.1% DMSO), 1385 
10O5, or AN2 for the indicated concentration for 24 hours; chloroquine (CQ, 20 μM) 1386 
treatment was used as a control. After 24 hours, cells were fixed, and images were 1387 
acquired with confocal microscopy. The number and size of GFP vesicles per cell was 1388 
determined by Image J software (n number indicated on top of each plot). For each 1389 
treatment, over 20,000 puncta were quantified (~100 puncta per cell in 226 cells). Scale 1390 
bar: 10 μm.  1391 
b) Representative images and quantifications of the numbers of autophagosomes (green+ 1392 
puncta) and autolysosomes (red+;green- puncta) in HeLa cells stably expressing 1393 
mRFP-GFP-LC3B. Scale bar: 10 μm. Autophagosome numbers or sizes were not 1394 
influenced by 10O5 and AN2 at indicated concentrations after 24 hours treatment (or 4 1395 
hours treatment, not shown). The autophagsome fusion was also unaffected as indicated 1396 
by the autolysosome number. Note that the autophagosome/autolysosome numbers/sizes 1397 
were based on image analysis of the puncta, some of which may reflect multiple vesicles. 1398 
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Green vesicles are considered to be autophagosomes (GFP+ puncta) and red vesicles 1399 
are considered to be both autophagosomes and autolysosomes. The number of 1400 
autolysosomes (RFP+ GFP- puncta) was achieved by subtracting the number of green 1401 
vesicles from that of the red vesicles. >10,000 puncta from 194 cells were analyzed.  1402 
c) Representative Western-blots and quantifications of HeLa cells stably expressing 1403 
GFP-LC3B. The “free GFP” was generated by lysosomal cleavage, and thus the “free 1404 
GFP”/”GFP-LC3B” ratio was used as an index for autophagy flux, which was unaffected 1405 
by 10O5 or AN2, but decreased by the autophagy flux inhibitor chloroquine (CQ).  1406 
d) Representative Western-blots and quantifications of the chase signal of long-lived 1407 
proteins in HeLa cells as an indicator of autophagy flux (see “Methods”). Consistent with 1408 
previous reports33, starvation reduced the long-live protein chase signal, whereas 1409 
rapamycin treatment had a milder effect. The mHTT-LC3 linker compounds 10O5 and 1410 
AN2 showed no influence in this assay.  1411 
e) Representative Western-blots and quantifications of LC3 in cultured cortical neurons 1412 
treated with the indicated compounds. Normalized LC3-II/LC3-I was used as the indicator 1413 
of autophagy. In the right panels, the 10O5 and AN2 concentrations were 100 nM and 50 1414 
nM, respectively. 1415 
f) The SQSTM1/p62 levels were tested by Western-blots for the cortical tissues from mice 1416 
injected by the indicated compounds or the DMSO control. Bars indicate mean and s.e.m.. 1417 
For all panels, the n numbers indicated in each bar indicate the cell numbers (a-b), the 1418 
number of independently plated wells (c-e) or mouse numbers (f). Error bars indicate 1419 
mean and s.e.m.. The statistical analysis was performed by one-way ANOVA with 1420 
post-hoc Dunnett’s tests for a-e, and by two-tailed unpaired t tests for f. Note that the 1421 
post-hoc tests were not performed if the ANOVA tests failed to show significance. “****”: 1422 
p<0.0001 (post-hoc). 1423 
 1424 
Extended Data Fig. 8. Investigation on the specificity of mHTT lowering effects of 1425 
mHTT-LC3 linker compounds. 1426 
a) Representative Western-blots and quantifications of cultured cortical neurons treated 1427 
with the indicated compounds. None of the proteins tested had an obvious change (> 1428 
10%). 1429 
b) Volcano plots of the proteomics analysis of cortices from ip-injected HD mice (10 m, 4 1430 
mice per group, injected for 14 days). The concentration injected was 0.5 mg/kg with 110 1431 
μg/kg DMSO, and equal amount of vehicle containing DMSO was injected as the controls. 1432 
Only those proteins detected in both groups of samples used for comparisons were 1433 
calculated and plotted. The dots plotted for HTT were pointed by red arrows. See 1434 
Supplementary Table 2 for complete datasets. The bar plots indicate the total HTT levels 1435 
normalized to the DMSO control. The actual mHTT reduction is anticipated to be more, 1436 
because the compounds reduced mHTT allele-selectively.  1437 
c) Similar to b), but in cultured cortical neurons (from p0 pups, 3 wells per group). See 1438 
Supplementary Table 3 for complete datasets.  1439 
In all panels, the error bars represent mean and s.e.m.. 1440 
 1441 
Extended Data Fig. 9. mHTT-LC3 linker compounds lowered the mutant ATXN3 1442 
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protein with polyQ expansion in an allele-selective manner. 1443 
a) Representative Western-blots and quantifications of ATXN3 levels in a SCA3 patient 1444 
fibroblast line treated with the indicated compounds. The lowering of mutant (Q74) but not 1445 
wild-type (Q27) ATXN3 was observed by treatment of linker compounds tested. 1446 
b) Quantification of the GFP intensity as an indicator of polyQ-sfGFP (25Q-GFP, 38Q-GFP, 1447 
46Q-GFP, and 72Q-GFP) protein levels in transfected HEK293T cells treated with the 1448 
indicated compounds using Incucyte. The lowering of 72Q-GFP, 46Q-GFP and 38Q-GFP, 1449 
but not 25Q-GFP was observed. 1450 
For both a) and b), the compound concentrations were 100 nM for 10O5 and AN1, and 50 1451 
nM for AN2. Bar plots present mean and s.e.m., and n numbers indicate independently 1452 
plated wells. 1453 
c) SDS-PAGE analysis of polyQ-sfGFP proteins (25Q, 38Q, 46Q, 53Q and 72Q) purified 1454 
from HEK293T cells. The protein purification methods were similar to the ones for HTT 1455 
proteins. 1456 
d) Binding of 10O5, AN1 and AN2 to sfGFP (GFP) or different polyQ-sfGFP (25Q-GFP, 1457 
38Q-GFP, 72Q-GFP) proteins in standard treated capillaries measured by MST, 1458 
performed and analyzed similarly as in Extended Data Fig. 2b. All these compounds 1459 
interact with 38Q-GFP and 72Q-GFP, but not 25Q-GFP or GFP. 1460 
e) Association-dissociation curves of surface immobilized compounds 10O5, AN1 and 1461 
AN2 with polyQ-sfGFP (72Q, 53Q, 46Q, 38Q and 25Q) proteins. For all 1462 
association-dissociation curves, vertical dash lines mark the starts of association and 1463 
dissociation phases of the binding event. The red dash curves are fits to a Langmuir 1464 
reaction model with the fitting parameters listed at the bottom of each plot. No binding 1465 
signals were observed for 25Q-sfGFP (25Q).  1466 
f-h) Results of mouse behavioral test performed similarly as in Fig. 5d-f, except that the 1467 
mice were injected with saline (0.9% NaCl) with DMSO (110 μg/kg) or without DMSO. The 1468 
statistical analysis was performed by two-way ANOVA with post-hoc Bonferroni’s tests, 1469 
and the F/p values and degrees of freedom were indicated in the table underneath each 1470 
plot.  1471 
In all panels, the error bars represent mean and s.e.m.. 1472 
 1473 
Extended Data Table 1. Summary of data on mHTT lowering or rescue of 1474 
HD-relevant phenotypes 1475 
A summary table showing the percentage lowering of the mHTT or HTT levels, as well as 1476 
the percentage rescue of HD-relevant phenotypes (normalized to the difference between 1477 
HD and WT) in different HD models assayed by different approaches under optimal 1478 
conditions. The corresponding data figures have been indicated in the middle column. The 1479 
percentage change/rescue were presented in the form of mean ± s.e.m.. 1480 
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Figure 1
a           Small molecule microarray (SMM)               b                        OI-RD screening signals                                                                              
 
c          Kon/Koff measurements for compound-HTTexon1 interactions         
d             Kon/Koff measurements for compound-LC3B interactions           
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   compound-HTT(full-length) interactions     
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Figure 2
a Cultured primary cortical neurons (HdhQ7/Q140) b  Cultured primary cortical neurons (HdhQ7/Q7)
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Figure 3
a                                               Primary human patient fibroblasts
b HD patient immortalized fibroblasts (Q47)
c HD patient immortalized fibroblasts (Q47) treated with other c-Raf or KSP inhibitors   
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Figure 4
a                          MBP/HTTexon1-MBP + LC3B                                     
b                        Full-length HTT + GST-LC3B/GST
                         
 
                                 
                
c                  Transfected HeLa cells (HTTexon1/LC3)
d                STHdhQ111/Q111 cells (mHTT/LC3-II)
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Figure 5
a                           Human iPSC-derived neurons (TUBB3/DAPI; -BDNF)                              
           WT                                                           HD(Q47)
          DMSO            DMSO            10O5               8F20                AN1                AN2
b  Human iPSC-derived neurons (-BDNF at 0 h)  c             Drosophila models expressing human full-length HTT
                         
d                                        Mouse rotarod tests                           e                        Mouse balance-beam tests
 
                                 
f                                Mouse gripping force tests                         g
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